<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7922936</article-id><article-id pub-id-type="pmid">33572621</article-id><article-id pub-id-type="doi">10.3390/ph14020111</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-14-00111</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>In Vitro Modulation of P-Glycoprotein Activity by <italic>Euphorbia intisy</italic> Essential Oil on Acute Myeloid Leukemia Cell Line HL-60R</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Poma</surname><given-names>Paola</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00111">1</xref></contrib><contrib contrib-type="author"><name><surname>Labbozzetta</surname><given-names>Manuela</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00111">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1828-7834</contrib-id><name><surname>Ramarosandratana</surname><given-names>Aro Vonjy</given-names></name><xref ref-type="aff" rid="af2-pharmaceuticals-14-00111">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2448-9192</contrib-id><name><surname>Rosselli</surname><given-names>Sergio</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00111">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5059-8686</contrib-id><name><surname>Tutone</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00111">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4731-7112</contrib-id><name><surname>Sajeva</surname><given-names>Maurizio</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00111">1</xref></contrib><contrib contrib-type="author"><name><surname>Notarbartolo</surname><given-names>Monica</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-14-00111">1</xref><xref rid="c1-pharmaceuticals-14-00111" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-pharmaceuticals-14-00111"><label>1</label>Department of Biological, Chemical and Pharmaceutical Science and Technology (STEBICEF), University of Palermo, 90128 Palermo, Italy; <email>paola.poma@unipa.it</email> (P.P.); <email>manuela.labbozzetta@unipa.it</email> (M.L.); <email>sergio.rosselli@unipa.it</email> (S.R.); <email>marco.tutone@unipa.it</email> (M.T.); <email>maurizio.sajeva@unipa.it</email> (M.S.)</aff><aff id="af2-pharmaceuticals-14-00111"><label>2</label>Department of Plant Biology and Ecology, University of Antananarivo, P.O. Box 906, Antananarivo 101, Madagascar; <email>arovonjy@yahoo.fr</email></aff><author-notes><corresp id="c1-pharmaceuticals-14-00111"><label>*</label>Correspondence: <email>monica.notarbartolo@unipa.it</email></corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>1</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2021</year></pub-date><volume>14</volume><issue>2</issue><elocation-id>111</elocation-id><history><date date-type="received"><day>13</day><month>12</month><year>2020</year></date><date date-type="accepted"><day>27</day><month>1</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><italic>Euphorbia</italic> species have a large spectrum of traditional medicinal uses. We tested the biological activities of the essential oil (EO) of <italic>Euphorbia intisy</italic> Drake in an acquired multidrug resistance leukemia model to assess whether the EO obtained by hydrodistillation of stems was able to reverse the resistant phenotype. HL-60R cell lines are characterized by the overexpression of P-glycoprotein (P-gp), inhibitors of apoptosis proteins (IAPs) and constitutive expression of NF-&#x003ba;B. EO chemical composition was determined by GC/MS analysis; cytotoxic activity of EO by MTS assay alone or in combination with doxorubicin; pro-apoptotic effect and doxorubicin accumulation were analyzed by flow cytometry; P-gp ATPase activity was measured by P-gp-Glo&#x02122; assay systems kit. The ability to inhibit NF-&#x003ba;B and its target genes was also assessed. <italic>E. intisy</italic> EO exhibited a comparable cytotoxic effect and ability to block P-gp in both the HL-60 and its MDR variant HL-60R. In addition, EO suppressed P-gp protein expression and significantly downregulated MDR1 mRNA level, as well as some IAPs proteins, probably through the inhibition of NF-&#x003ba;B. Our results suggest that <italic>E. intisy</italic> EO could reverse P-gp-mediated drug resistance in tumor cells acting as a chemosensitizing agent. </p></abstract><kwd-group><kwd>essential oil</kwd><kwd>cancer cell</kwd><kwd>P-glycoprotein</kwd><kwd>multidrug resistance</kwd><kwd>myeloid leukemia cell</kwd><kwd>NF-&#x003ba;B</kwd><kwd>inhibitors of apoptosis proteins</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-14-00111"><title>1. Introduction</title><p>Multidrug resistance (MDR), which is often of a multiple type, is a real obstacle to the pharmacological treatment of many types of cancer diseases and can be defined as the ability of cancer cells to acquire resistance to both conventional and novel chemotherapy agents [<xref rid="B1-pharmaceuticals-14-00111" ref-type="bibr">1</xref>]. In this paper we focus on drug resistance acquired after treatment with a chemotherapic drug which is a complex and multifactorial phenomenon.</p><sec id="sec1dot1-pharmaceuticals-14-00111"><title>1.1. P-Glycoprotein Mediated Drug Resistance</title><p>In the MDR process a key role is played by P-glycoprotein (P-gp), a drug efflux pump which is responsible for the decrease in intracellular drug accumulation. P-gp is the most studied drug efflux pumps, described for the first time by Juliano and Ling [<xref rid="B2-pharmaceuticals-14-00111" ref-type="bibr">2</xref>]. It is part of a vast superfamily of ATP-dependent transporters, a glycoprotein with a molecular weight of about 170 kDa encoded by human gene ATP-binding cassette sub-family B member 1 (ABCB1) or Multi Drug Resistance 1 (MDR1), consists of a dozen transmembrane domains of six extracellular loops and two adenosine triphosphate (ATP) binding sites. The physiological role of P-gp, present in different tissues such as the liver, blood&#x02013;brain barrier, lymphocytes, testicles, placenta, small and large intestines, is to protect and regulate the absorption, distribution, and excretion of xenobiotics and drugs. Numerous molecules have been proposed to bypass the multidrug resistance due to the overexpression of P-gp. The main pharmacological strategy of preclinical and clinical research to overcome MDR and revert the resistant phenotype is represented by the co-administration of anticancer chemotherapy drug and P-gp substrate-inhibitor compounds in order to restore the effective therapeutic concentration of the drug in the tumor resistant cells [<xref rid="B3-pharmaceuticals-14-00111" ref-type="bibr">3</xref>]. The P-gp inhibition can occur by molecules that compete for the binding site with the substrate, or by non-competitive or allosteric inhibition, blocking ATP hydrolysis and altering the lipid layer of cell membranes or affecting P-gp expression. In this context, natural products are considered as a new source of drugs to be used in multidrug resistant diseases and a valid alternative therapy to those currently in use. Some secondary metabolites isolated from different plants were reported as P-gp expression or activity inhibitors, such as flavonoids, coumarins, terpenoids, alkaloids, and steroidal saponins [<xref rid="B4-pharmaceuticals-14-00111" ref-type="bibr">4</xref>].</p><p>Previous works demonstrated that essential oils (EOs), from succulent plants, have antitumor activities on different types of tumors such as triple negative breast cancer and acute myeloid leukemia all characterized by scarce responsiveness to chemotherapeutic drugs [<xref rid="B5-pharmaceuticals-14-00111" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceuticals-14-00111" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceuticals-14-00111" ref-type="bibr">7</xref>]. The biological effects showed that the EOs extracted by the hydrodistillation of leaves seem to be due to the presence of terpene compounds such as phytol. A recent analysis suggests that we must diversify the species we utilize and/or substitute towards those better adapted to future climate [<xref rid="B8-pharmaceuticals-14-00111" ref-type="bibr">8</xref>]. Succulent plants could represent advantageous alternatives, thanks to their ability to sustain growth in arid environment [<xref rid="B9-pharmaceuticals-14-00111" ref-type="bibr">9</xref>]. Varying sources of bioactive compounds with drought-tolerant species appears to be a convenient option in drug discovery, as it links the usefulness with the resilience. Furthermore, pharmacological investigations on their medicinal properties are promising for several contemporary diseases [<xref rid="B10-pharmaceuticals-14-00111" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceuticals-14-00111" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceuticals-14-00111" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceuticals-14-00111" ref-type="bibr">13</xref>].</p></sec><sec id="sec1dot2-pharmaceuticals-14-00111"><title>1.2. The Genus Euphorbia Uses</title><p>The genus <italic>Euphorbia</italic> L. (Family: Euphorbiaceae) is distributed in different parts of the world, identifiable by the white latex and unique inflorescences [<xref rid="B14-pharmaceuticals-14-00111" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceuticals-14-00111" ref-type="bibr">15</xref>]. However, species with succulent traits are mostly found in arid areas and represented in subgenera Athymalus and <italic>Euphorbia</italic> [<xref rid="B16-pharmaceuticals-14-00111" ref-type="bibr">16</xref>]. <italic>Euphorbia</italic> species have a large spectrum of traditional medicinal uses [<xref rid="B17-pharmaceuticals-14-00111" ref-type="bibr">17</xref>] ranging from digestive system disorders, skin aliments, infections/infestations, injuries/inflammations and respiratory complaints; some species are cited as vertebrate poisons [<xref rid="B18-pharmaceuticals-14-00111" ref-type="bibr">18</xref>]. These knowledges are supported by a broad range of biological properties and potential usages in derived natural products [<xref rid="B19-pharmaceuticals-14-00111" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceuticals-14-00111" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceuticals-14-00111" ref-type="bibr">21</xref>]. A considerable amount of literature has been also published on the anticancer activities of <italic>Euphorbia</italic>; these are mostly ascribed to a variety of terpenic compounds acting on different pathways of tumor formation [<xref rid="B22-pharmaceuticals-14-00111" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceuticals-14-00111" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceuticals-14-00111" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceuticals-14-00111" ref-type="bibr">25</xref>].</p><p>Chemical composition of <italic>Euphorbia</italic> EOs is largely studied: e.g., <italic>E. acanthothamnos</italic>, <italic>E. apios</italic>, <italic>E. characias</italic>, <italic>E. dendroides</italic>, <italic>E. helioscopia</italic>, and <italic>E. rigida</italic> with nonanal, germacrene, phytol, &#x003b2;-caryophyllene, heneicosane, and heptacosane as major components [<xref rid="B26-pharmaceuticals-14-00111" ref-type="bibr">26</xref>], <italic>E. teheranica</italic> with elemol as major component [<xref rid="B27-pharmaceuticals-14-00111" ref-type="bibr">27</xref>], <italic>E. caracasana</italic> and <italic>E. cotinifolia</italic> with &#x003b2;-caryophyllene as a major component [<xref rid="B28-pharmaceuticals-14-00111" ref-type="bibr">28</xref>], and <italic>E. heterophylla</italic> with 1,8-cineole as major component [<xref rid="B29-pharmaceuticals-14-00111" ref-type="bibr">29</xref>].</p><p>However, there are few studies that have investigated their potential anticancer capacities. <italic>Euphorbia</italic> species occurring in Southern Africa and Madagascar produce a high diversity of diterpenoids possibly because of an adaptive pressure exerted by not yet described herbivores [<xref rid="B16-pharmaceuticals-14-00111" ref-type="bibr">16</xref>]. Indeed, the southern arid zone of Madagascar is a hotspot for <italic>Euphorbia</italic> with more than 170 native species [<xref rid="B30-pharmaceuticals-14-00111" ref-type="bibr">30</xref>]. <italic>Euphorbia</italic> is locally classified among the top 5 species-rich genera with medicinal properties [<xref rid="B31-pharmaceuticals-14-00111" ref-type="bibr">31</xref>]. <italic>Euphorbia intisy</italic> Drake (<xref ref-type="fig" rid="pharmaceuticals-14-00111-f001">Figure 1</xref>) is a tree-like succulent of the dry spiny forests whose exploitation dates to the end of the 19th century, boosted by the strong European demand for latex [<xref rid="B32-pharmaceuticals-14-00111" ref-type="bibr">32</xref>]. <italic>E. intisy</italic> provides rubber with high quality latex and low resin contents from trunks and roots [<xref rid="B33-pharmaceuticals-14-00111" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceuticals-14-00111" ref-type="bibr">34</xref>]. The latex itself is not toxic, however, the seeds are toxic and cause vomiting, severe bowel disturbance, and heartburn [<xref rid="B35-pharmaceuticals-14-00111" ref-type="bibr">35</xref>]. <italic>E. intisy</italic> was nearly made extinct by overexploitation, in the beginning of the 20th century [<xref rid="B36-pharmaceuticals-14-00111" ref-type="bibr">36</xref>]. It is now classified as Near Threatened according to the IUCN red list [<xref rid="B37-pharmaceuticals-14-00111" ref-type="bibr">37</xref>]. <italic>E. intisy</italic> is cultivated in the open ground at the Botanical Garden of Palermo. It is easily propagated by cuttings and therefore enough material for experiments can be obtained with no damages to wild populations, showing to be a good candidate to investigations on its chemical composition and biological activities.</p><p>For all previously made assumptions we used a multidrug resistance leukemia model obtained by us by exposure of the sensitive cell line HL-60 with increasing doses of doxorubicin, characterized by overexpression of P-gp, inhibitor of apoptosis proteins (IAPs) and constitutive expression of the transcription factor NF-&#x003ba;B, to assess whether the EO extracted from <italic>Euphorbia intisy</italic> leaves was able to reverse the resistant phenotype.</p></sec></sec><sec sec-type="results" id="sec2-pharmaceuticals-14-00111"><title>2. Results and Discussion</title><sec id="sec2dot1-pharmaceuticals-14-00111"><title>2.1. Chemical Composition</title><p>The yield in essential was 0.0034%. The plants from which the stems were collected were not affected by the removal of the stems and they completed their vegetative cycle and flowered in the following years. In the essential oil of <italic>E. intisy</italic>, we detected 70 compounds (<xref rid="pharmaceuticals-14-00111-t001" ref-type="table">Table 1</xref> and <xref ref-type="app" rid="app1-pharmaceuticals-14-00111">Figure S1</xref>) accounting 68.79% of the whole composition. Only compounds that showed mass spectral similarities &#x02265;80% in respect to our libraries were considered [<xref rid="B38-pharmaceuticals-14-00111" ref-type="bibr">38</xref>,<xref rid="B39-pharmaceuticals-14-00111" ref-type="bibr">39</xref>] and NIST11. The composition was dominated by terpenoids with 48 compounds covering 37.98% of the total EO composition. Sesquiterpene alcohols and sequiterpene hydrocarbons where the classes with the higher number of compounds. Phytol and isophytol are the only diterpene, and phytol alone covers 9.55% of the whole EO composition. Mammals are generally able to use phytol, as they would do with any fatty acid, as a source of energy through its beta-oxidation [<xref rid="B40-pharmaceuticals-14-00111" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceuticals-14-00111" ref-type="bibr">41</xref>]. Recent studies on phytol have shown effects as a function of anxiolytic, metabolism modulator, cytotoxicity, antioxidant, autophagy, and induction to apoptosis, antinociceptive, anti-inflammatory, immunity modulator, and bactericide [<xref rid="B42-pharmaceuticals-14-00111" ref-type="bibr">42</xref>]. Recently Poma et al. [<xref rid="B6-pharmaceuticals-14-00111" ref-type="bibr">6</xref>] showed that the essential oils of two succulent plants, rich in phytol, interfere with NF-&#x003ba;B on human cancer cell lines. Aliphatic compounds were the second most abundant class (22.89%), and heptacosane with 15.73% was the most abundant aliphatic compound and the most abundant one of the whole EO. Heptacosane falls into the category of phytoecdysteroids that mimic the biological function of the insect mover hormone, interfering with the synthesis of chitin, thus not allowing induction to the moult and metamorphosis [<xref rid="B43-pharmaceuticals-14-00111" ref-type="bibr">43</xref>]. This also may play a role in plant defense against insects. Benzyl benzoate is the only aromatic compound found in the EO of <italic>E. insity</italic>. It is a powerful acaricide [<xref rid="B44-pharmaceuticals-14-00111" ref-type="bibr">44</xref>]. The ketone compounds found in <italic>E. intisy</italic> are the isomer (Z)-jasmone (0.23%) that is produced by some plants and can act both as an attractor and as a repellent for various insects [<xref rid="B45-pharmaceuticals-14-00111" ref-type="bibr">45</xref>], and hexahydrofarnesyl-acetone (0.35%) that appears to be an antimicrobial for bacteria and fungi [<xref rid="B46-pharmaceuticals-14-00111" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceuticals-14-00111" ref-type="bibr">47</xref>]. Some of the compounds identified in <italic>E. intisy</italic> are found in the EOs of other <italic>Euphorbia</italic> species (as reported in the introduction): nonanal, phytol, heneicosane, heptacosane, and beta-elemol [<xref rid="B27-pharmaceuticals-14-00111" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceuticals-14-00111" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceuticals-14-00111" ref-type="bibr">29</xref>]. Three compounds, accounting for 7.60%, were not identified and are reported in <xref rid="pharmaceuticals-14-00111-t001" ref-type="table">Table 1</xref> with their mass spectra.</p></sec><sec id="sec2dot2-pharmaceuticals-14-00111"><title>2.2. In Vitro Cytotoxic and Cell Death Effects of E. intisy Essential Oil</title><p>In this paper, we focus on drug resistance acquired after drug treatment with chemotherapy which is a complex and multifactorial phenomenon. The HL-60 is a chemosensitive cell line, whereas HL-60R cells is resistant to doxorubicin as well as other chemotherapeutic drugs [<xref rid="B48-pharmaceuticals-14-00111" ref-type="bibr">48</xref>]. The HL-60 cell line and its multidrug resistance variant HL-60R were treated with different concentration of <italic>E. intisy</italic> EO for 72 h. The essential oil induced cell growth inhibition in a concentration-dependent way in the two cell lines with IC<sub>50</sub> values quite similar with low cytotoxicity in differentiated Caco-2 cells (<xref ref-type="fig" rid="pharmaceuticals-14-00111-f002">Figure 2</xref>, <xref rid="pharmaceuticals-14-00111-t002" ref-type="table">Table 2</xref>). Interestingly, Poma et al. [<xref rid="B6-pharmaceuticals-14-00111" ref-type="bibr">6</xref>] found similar results with the EOs of two succulent plants rich in phytol.</p><p>The HL-60 and HL-60R cell lines were incubated with the essential oil (25 &#x000b5;g/mL) for 24 h, and cell death was evaluated by flow cytometry analysis of DNA stained with propidium iodide. <italic>E. intisy</italic> EO caused a comparable marked block in the preG<sub>0</sub>-G<sub>1</sub> position in both cell lines by preventing the entry of cells to G2/M (<xref ref-type="fig" rid="pharmaceuticals-14-00111-f003">Figure 3</xref>). These results confirm the interest in <italic>Euphorbia</italic> species as potential anticancer drugs [<xref rid="B49-pharmaceuticals-14-00111" ref-type="bibr">49</xref>].</p></sec><sec id="sec2dot3-pharmaceuticals-14-00111"><title>2.3. E. intisy Essential Oil Treatment Inhibits the Activation of The NF-&#x003ba;B Signaling Pathway</title><p>The multidrug resistant variant HL-60R is characterized by constitutive expression of NF-&#x003ba;B in respect to HL-60 [<xref rid="B50-pharmaceuticals-14-00111" ref-type="bibr">50</xref>]. In order to evaluate if <italic>E. intisy</italic> EO could interfere in the NF-&#x003ba;B DNA binding capacity, HL-60 and HL-60R cell lines were treated with 25 &#x000b5;g/mL of essential oil for 24 h. We observed a strong reduction of NF-&#x003ba;B DNA-binding activity only in HL-60R cells (<xref ref-type="fig" rid="pharmaceuticals-14-00111-f004">Figure 4</xref>). Previous papers [<xref rid="B48-pharmaceuticals-14-00111" ref-type="bibr">48</xref>,<xref rid="B50-pharmaceuticals-14-00111" ref-type="bibr">50</xref>] highlighted that HL-60R cells are characterized by an overexpression of P-gp, Bcl-2 and IAPs. Moreover, the treatment with the essential oil also caused a substantial mRNA and protein decrease of some NF-&#x003ba;B target genes, in particular antiapoptotic factors such as Survivin, XIAP, Bcl-2, and the multidrug efflux transporter P-glycoprotein (<xref ref-type="fig" rid="pharmaceuticals-14-00111-f005">Figure 5</xref> and <xref ref-type="fig" rid="pharmaceuticals-14-00111-f006">Figure 6</xref>). Previous works demonstrated that the antiproliferative and pro-apoptotic activities of essential oils extracted from some species of succulent plants can interfere with NF-&#x003ba;B pathway in the same cellular model [<xref rid="B6-pharmaceuticals-14-00111" ref-type="bibr">6</xref>]. Based on these results, we speculate that the transcriptional changes in P-gp and IAPs are primary effects and that these modifications induce cytotoxicity. These results corroborate the idea that EOs extracted from succulent plants rich in phytol interfere with NF-&#x003ba;B pathway in MDR models.</p></sec><sec id="sec2dot4-pharmaceuticals-14-00111"><title>2.4. Effects of E. Intisy EO on Intracellular Accumulation of Doxorubicin in HL-60R Cell Line</title><p>Due to the strong reduction of mRNA and protein level of P-gp under treatment with essential oil in our cell lines, we investigated the possible involvement of the EO in the drug resistance mechanism. P-gp-overexpressing cells show significant decreases in drug accumulation compared to non-P-gp-expressing. In order to evaluate the effects of <italic>E. intisy</italic> EO on intracellular accumulation of doxorubicin, a P-gp substrate anticancer drug, HL-60 and HL-60R cells were treated with EO 15 &#x003bc;g/mL for 24 h. After this incubation, doxorubicin 1 &#x003bc;g/mL was added for different times (30 min, 1 h and 2 h). The intracellular accumulation of doxorubicin was measured by flow cytometric analysis. The results are presented as percentage of fluorescence intensity in HL-60 (<xref ref-type="fig" rid="pharmaceuticals-14-00111-f007">Figure 7</xref>) and HL-60R (<xref ref-type="fig" rid="pharmaceuticals-14-00111-f008">Figure 8</xref>).</p><p>The results indicate a significant increase in fluorescence in HL-60R of the samples pretreated with <italic>E. intisy</italic> essential oil, showing an intracellular accumulation of doxorubicin after exposure at different times. Unexpectedly, in HL-60 the pretreatment with EO reduces the accumulation of doxorubicin (only 2 h after treatment with doxorubicin) in respect to its control. These data could suggest that in HL-60R cells <italic>E. intisy</italic> EO acts like an inhibitor of P-gp function, as verapamil that produced similar results on doxorubicin accumulation (<xref ref-type="fig" rid="pharmaceuticals-14-00111-f007">Figure 7</xref>, <xref ref-type="fig" rid="pharmaceuticals-14-00111-f008">Figure 8</xref> and <xref rid="pharmaceuticals-14-00111-t003" ref-type="table">Table 3</xref>). These results are in accordance with the finding of Fidyt et al. [<xref rid="B49-pharmaceuticals-14-00111" ref-type="bibr">49</xref>] who demonstrated that oxygenated terpenes potentiate the classical drug efficacy by augmenting their concentrations inside the cells. It is interesting to note that despite <italic>E. intisy</italic> EO shows a lower accumulation of doxorubicin in respect to verapamil, it has a low cytotoxic effect (<xref rid="pharmaceuticals-14-00111-t002" ref-type="table">Table 2</xref>).</p></sec><sec id="sec2dot5-pharmaceuticals-14-00111"><title>2.5. Effects of E. intisy EO on P-gp Activity</title><p>P-gp functions as an ATP-dependent drug efflux pump. The compounds that are substrates for transport by P-gp typically stimulate its ATPase activity. We performed the P-gp-Glo&#x02122; Assay that detects a luminescent signal inversely proportional to the ATP consumption. </p><p>As shown in <xref ref-type="fig" rid="pharmaceuticals-14-00111-f009">Figure 9</xref>, the essential oil of <italic>E. intisy</italic> increased basal P-gp ATPase activity in a dose-dependent way.</p><p>To further confirm these outcomes, we performed the same assay adding verapamil in the wells treated with EO and the results are shown in <xref ref-type="fig" rid="pharmaceuticals-14-00111-f010">Figure 10</xref>. The data obtained demonstrated that EO not only stimulated basal P-gp ATPase activity, but also increased verapamil-stimulated P-gp ATPase activity. These results suggested that EO might be a stimulator of ATP-dependent drug efflux transporter, acting as substrate for transport by P-gp that stimulates P-gp ATPase activity, and lead to the inhibition of P-gp efflux function, in the same way verapamil acts. </p><p>Eid et al. [<xref rid="B51-pharmaceuticals-14-00111" ref-type="bibr">51</xref>] indicates that, among others, lipophilic terpenoids are probably competitive inhibitors of P-gp in cancer cells. Devanjee at al. [<xref rid="B3-pharmaceuticals-14-00111" ref-type="bibr">3</xref>] report that terpenoids possess significant P-gp inhibitory activity via different mechanisms. According to Wortelboer et al. [<xref rid="B52-pharmaceuticals-14-00111" ref-type="bibr">52</xref>] citral inhibits MRP1 and MRP2. In particular, Duarte et al. [<xref rid="B22-pharmaceuticals-14-00111" ref-type="bibr">22</xref>] identified latilagascene B, latilagascene E, and latilagascene D as inhibitors of P-gp that directly blocking its active sites. Some terpenoids can inhibit P-gp activity via binding with its active sites [<xref rid="B53-pharmaceuticals-14-00111" ref-type="bibr">53</xref>,<xref rid="B54-pharmaceuticals-14-00111" ref-type="bibr">54</xref>,<xref rid="B55-pharmaceuticals-14-00111" ref-type="bibr">55</xref>]. It is interesting to note that in a recent review Kemboi et al. [<xref rid="B17-pharmaceuticals-14-00111" ref-type="bibr">17</xref>] described the effects of terpenoids from some <italic>Euphorbia</italic> species like a possible multi-drug resistance reverting agents in comparison to verapamil. </p></sec><sec id="sec2dot6-pharmaceuticals-14-00111"><title>2.6. Cytotoxic and Cell Death Effects of E. intisy EO in Combination with Doxorubicin</title><p>Given the results obtained, we wanted to verify whether the increasing intracellular accumulation of doxorubicin caused by <italic>E. intisy</italic> EO would lead to greater cytotoxic effects of doxorubicin in HL-60R. The effects of <italic>E</italic>. <italic>intisy</italic> EO and doxorubicin alone or in combination on the inhibition of cell growth were evaluated using MTS assays, while cell death was evaluated by flow cytometry analysis of DNA stained with propidium iodide. In <xref rid="pharmaceuticals-14-00111-t004" ref-type="table">Table 4</xref>, we report the percentages of cell growth inhibition by EO and doxorubicin treatments alone. As expected, <italic>E. intisy</italic> EO carried out a strong potentiation effects of doxorubicin in terms of cell growth inhibition in HL-60 R, as indicated by the combination indices (<xref rid="pharmaceuticals-14-00111-t005" ref-type="table">Table 5</xref>). The combination of the essential oil (25 &#x000b5;g/mL) and doxorubicin at different concentrations in HL-60R cells also caused a significant potentiation in the induction of cell death (<xref rid="pharmaceuticals-14-00111-t006" ref-type="table">Table 6</xref> and <xref ref-type="app" rid="app1-pharmaceuticals-14-00111">Figure S2</xref>).</p><p>Our results agree with those reported by Neto et al. [<xref rid="B56-pharmaceuticals-14-00111" ref-type="bibr">56</xref>] and Reies et al. [<xref rid="B57-pharmaceuticals-14-00111" ref-type="bibr">57</xref>] that show that <italic>Euphorbia</italic> secondary metabolites were more efficient than verapamil in reverting MDR phenotypes. For this reason, we hypothesize that <italic>E. intisy</italic> EO can represent an effective and non-toxic P-gp inhibitor to reverse P-gp-mediated multidrug resistance and improve the potency of anticancer drugs.</p></sec></sec><sec id="sec3-pharmaceuticals-14-00111"><title>3. Material and Methods</title><sec id="sec3dot1-pharmaceuticals-14-00111"><title>3.1. Plant Species</title><p><italic>Euphorbia intisy</italic> Drake, known locally as &#x0201c;Herotse&#x0201d; or &#x0201c;Horotsy&#x0201d;, is a cactiform shrub of the Southern Malagasy dry forest attaining 4 to 7 m. It belongs to the section Pervilleanae of the Euphorbiaceae that groups together seven species which are strictly Malagasy [<xref rid="B30-pharmaceuticals-14-00111" ref-type="bibr">30</xref>]. Trunk is upright and branched at the base. Young stems are dichotomously branched with leaves reduced to scales (almost leafless). Root system are swollen displaying a strategy to store water in xeric conditions [<xref rid="B33-pharmaceuticals-14-00111" ref-type="bibr">33</xref>]. <italic>E. intisy</italic> was nearly made extinct by massive exploitation in the beginning of the 20th century [<xref rid="B36-pharmaceuticals-14-00111" ref-type="bibr">36</xref>]. It is now classified as Near Threatened according to the IUCN red list [<xref rid="B37-pharmaceuticals-14-00111" ref-type="bibr">37</xref>].</p></sec><sec id="sec3dot2-pharmaceuticals-14-00111"><title>3.2. Plant Material</title><p>Unlignified stems of <italic>Euphorbia intisy</italic> were collected in September 2018 from plants cultivated in the open air at the Botanical Garden of the University of Palermo. The plants were raised from seeds in 1984 with reference code: Euphorbiaceae N.19.C. The matrices were placed in paper bags and kept at &#x02212;30 &#x000b0;C for 24 h before hydrodistillation. No specific permits were required for the collection of plant material because the plants are part of the living collection of the Botanical Garden of the University of Palermo and the authors have access to that. The plant species used in the present study is listed in CITES Appendix II together with all succulent Euphorbiae and therefore seeds are exempt from the provisions of CITES. The seeds were obtained, and the plants raised before the Convention on Biological Diversity (CBD) entered into force on 29 December 1993 and therefore are pre-CBD specimens.</p></sec><sec id="sec3dot3-pharmaceuticals-14-00111"><title>3.3. Essential Oil</title><p>Stems (500 g) were hand-cut into small pieces (~2 cm) and hydrodistillated for 3 h in a Clevenger-type apparatus, using <italic>n</italic>-pentane as collection solvent [<xref rid="B58-pharmaceuticals-14-00111" ref-type="bibr">58</xref>]. The oil was dried by anhydrous sodium sulphate and stored at &#x02212;30 &#x000b0;C until chemical analysis and pharmacological tests. The essential oil yield was 12.93 mg. To prepare the stock solution for biological studies 2 mg of essential oil were dissolved in 1 ml of dimethyl sulfoxide (DMSO).</p></sec><sec id="sec3dot4-pharmaceuticals-14-00111"><title>3.4. Gas Chromatography-Mass Spectrometry</title><p>Essential oil of <italic>E. intisy</italic> was analyzed by GC-MS on a single quadrupole Shimadzu GC-MS-QP2010 (Kyoto, Japan) Plus equipped with an AOC-20i autoinjector (Shimadzu, Kyoto, Japan) and a Supelcowax 10 capillary column (30 m long, 0.25 mm i.d., 0.25 &#x003bc;m film thickness). One &#x003bc;L of diluted samples (1/100 <italic>v/v</italic>, in n-pentane) was injected at 250 &#x000b0;C in a split ratio of 1:1, and the column flow (carrier gas: helium) was set at 1 mL/min. The GC oven temperature was held for 5 min at 40 &#x000b0;C, then increased by 2 &#x000b0;C/min to 180 &#x000b0;C, held for 60 min, and finally raised to 240 &#x000b0;C at 10 &#x000b0;C/min. The MS interface worked at 280 &#x000b0;C, and the ion source at 250 &#x000b0;C. Mass spectra were taken at 70 eV (in EI mode) from <italic>m/z</italic> 30 to 600. The GC/MS data were analyzed using the GCMSolution package, Version 4.11.</p></sec><sec id="sec3dot5-pharmaceuticals-14-00111"><title>3.5. Identification of Compounds </title><p>The identification of compounds was carried out using the mass spectral libraries in respect to our libraries were considered [<xref rid="B38-pharmaceuticals-14-00111" ref-type="bibr">38</xref>,<xref rid="B39-pharmaceuticals-14-00111" ref-type="bibr">39</xref>], and NIST11. We only considered compounds which showed mass spectral similarities &#x0003e; 80% in respect to our libraries. Kovats retention indices were calculated using a series of n-alkanes (C10-C30).</p></sec><sec id="sec3dot6-pharmaceuticals-14-00111"><title>3.6. Cell Lines</title><p>The HL-60 cells were obtained from ATCC&#x000ae; (CCL-240, Rockville, MD, USA), while its variant HL-60R were cultured as previously described [<xref rid="B6-pharmaceuticals-14-00111" ref-type="bibr">6</xref>]. Caco-2 cells was kindly provided by Professor Mario Allegra (Department of Biological, Chemical and Pharmaceutical Science and Technology, University of Palermo, Italy). HL-60 and HL-60R cells were cultured in Roswell Park Memorial Institute (RPMI) 1640, while Caco-2 cells were cultured in Dulbecco&#x02019;s Modified Eagle Medium (DMEM) (HyClone Europe Ltd., Cramlington, UK) supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 units /mL penicillin and 100 &#x000b5;g/mL streptomycin (all reagents were from HyClone Europe Ltd., Cramlington, UK) in a humidified atmosphere at 37 &#x000b0;C in 5% CO<sub>2</sub>. Caco-2 cells were treated 15 days after confluence, at which time the cells are differentiated in normal intestinal-like cells.</p></sec><sec id="sec3dot7-pharmaceuticals-14-00111"><title>3.7. Cell Growth Assays</title><p>The cells were seeded at 5 &#x000d7; 10<sup>3</sup> cells/well onto 96-well plates and incubated overnight at 37 &#x000b0;C. At time 0, the medium was replaced with fresh complete medium supplemented with the substances (<italic>E. intisy</italic> EO, doxorubicin, or their combinations) at the indicated concentrations. Following 72 h of treatment, 15 &#x000b5;L commercial solution obtained from Promega Corp. (Madison, WI, USA) containing 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium (MTS) and phenazine ethosulfate was added. The plates were incubated in a humidified atmosphere at 37 &#x002da;C in 5% CO<sub>2</sub> for 2 h, and the bioreduction of MTS dye was evaluated by measuring the absorbance of each well at 490 nm using a microplate absorbance reader (iMark Microplate Reader; Bio-Rad Laboratories, Inc., Hercules, CA, USA). Cell growth inhibition was expressed as a percentage of the absorbance of the control cells. For the combinations, to evaluate the type of interaction between the agents, dose-effect curves were analyzed according to the Chou and Talalay method [<xref rid="B59-pharmaceuticals-14-00111" ref-type="bibr">59</xref>] using CalcuSyn&#x000ae; software (version 2.1; Biosoft, Cambridge, UK) as a non-constant ratio combination. The combination index (CI) indicates a quantitative measure of the degree of drug interaction in terms of synergistic (CI &#x0003c; 1), additive (CI = 1) or antagonistic (CI &#x0003e; 1) effects.</p></sec><sec id="sec3dot8-pharmaceuticals-14-00111"><title>3.8. Evaluation of Cell Death by Flow Cytometry </title><p>The cells were collected and washed twice with ice-cold PBS and then resuspended in a hypotonic fluorochrome solution containing propidium iodide (PI) 50 &#x000b5;g/mL in 0.1% sodium citrate plus 0.03% (<italic>v/v</italic>) Nonidet P-40, at 1 &#x000d7; 10<sup>6</sup>/mL. After incubation (at least 1 h at 4 &#x000b0;C) in this solution, the samples were filtered through nylon cloth, 40 &#x000b5;m mesh, and their fluorescence was analyzed using a FACSCanto instrument (Becton Dickinson, Montain View, CA, USA). The data were analyzed with BD FACSDiva software v.6.1.2. (Becton Dickinson). Cell death was determined by evaluating the percentage of events accumulated in the preG<sub>0</sub>-G<sub>1</sub> position [<xref rid="B48-pharmaceuticals-14-00111" ref-type="bibr">48</xref>].</p></sec><sec id="sec3dot9-pharmaceuticals-14-00111"><title>3.9. NF-&#x003ba;B Activation </title><p>The DNA binding capacity of NF-&#x003ba;B (p65 subunit) was measured in the nuclear extracts of cells treated using the TransAM NF-&#x003ba;B and Nuclear ExtractTM Kits (Active Motif, Carlsbad, CA, USA) according to the manufacturer&#x02019;s instructions. The results were expressed as arbitrary units: One unit is the DNA binding capacity shown by 2.5 &#x000b5;g of whole cell extract from Jurkat cells stimulated with 12-Otetradecanoylphorbol-13-acetate (TPA) + calcium ionophore (CI)/&#x000b5;g protein of HL-60/R nuclear extracts. </p></sec><sec id="sec3dot10-pharmaceuticals-14-00111"><title>3.10. Extraction of Cellular RNA and Reverse Transcription-Quantitative PCR (RT-qPCR) </title><p>Total RNA was extracted from cell lines using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). For the evaluation of gene expression, RNA was reverse transcribed using a high-capacity complementary DNA (cDNA) reverse transcription kit (Applied Biosystems Life Technologies Inc., Foster City, CA, USA). The resulting cDNAs were subjected to real-time RT-PCR using the TaqMan Gene Expression Master Mix kit (Applied Biosystems Life Technologies Inc., Foster City, CA, USA) in triplicates. The PCR cycling conditions were as follows: Denaturation at 50 &#x000b0;C for 2 min, annealing at 95 &#x000b0;C for 10 min, followed by 40 cycles of 95 &#x000b0;C for 15 sec and extension at 60 &#x000b0;C for 60 min. The running of the samples and data collection were performed on a StepOne AB Real Time PCR system (Applied Biosystems Life Technologies Inc., Foster City, CA, USA). &#x003b2;-actin was used as an internal standard. The specific TaqMan Assay used were: Survivin Hs00153353, XIAP Hs00236913, Bcl-2 Hs00236329, ABCB1 Hs00184005 (Applied Biosystems Life Technologies Inc., Foster City, CA, USA). Relative expression was calculated using the comparative Ct method [&#x02206;Ct = Ct(target gene)&#x02212;Ct(housekeeping gene)]. Where Ct was the fractional cycle number at which the fluorescence of each sample passed the fixed threshold. Fluorescence was measured at 515&#x02013;518 nm using StepOne AB Real Time PCR System software (Applied Biosystems Life Technologies Inc., Foster City, CA, USA). The &#x02206;&#x02206;Ct method was used to determine gene expression levels. &#x02206;&#x02206;Ct was calculated using the formula: &#x02206;&#x02206;Ct = &#x02206;Ct<sub>(each sample)</sub>&#x02212;&#x02206;Ct<sub>(reference sample)</sub>. Fold change was calculated using the 2 <sup>&#x02212;&#x02206;&#x02206;Ct</sup> equation. </p></sec><sec id="sec3dot11-pharmaceuticals-14-00111"><title>3.11. Western Blot Analysis </title><p>The whole-cell lysates were obtained from HL-60R cells using radioimmunoprecipitation assay buffer (Santa Cruz Biotechnology Inc., Dallas, TX, USA) and 25 &#x000b5;g protein was subjected to 10% SDS-PAGE and transferred to nitrocellulose membrane (Amersham, Pharmacia Biotech, Milan, Italy) using a semi-dry fast blot apparatus (Bio-Rad, Milan, Italy). Membranes were blocked with 5% (<italic>w/v</italic>) BSA in PBS-0.1% (<italic>v/v</italic>) Tween 20 for 1 h and then filters were incubated with primary antibodies raised against GAPDH (1:20,000; Sigma-Aldrich Srl, Milan, Italy.), XIAP (1:500; Cell Signaling Technology, Inc. Danvers, MA, USA), survivin (1:2000, Abcam Limited, Cambridge, UK), Bcl-2 ( 1:1000, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and P-gp (1:100, Invitrogen, Milan, Italy). The hybridization was visualized using an enhanced chemiluminescence detection kit (SuperSignal West Femto Maximum Sensitivity Substrate, Thermo Scientific Life Technologies Italia, Monza, Italy) and the Versa DOC imaging system (BioRad Laboratories, Milan, Italy). Immunoblots were quantified by densitometry and results were expressed as arbitrary units (protein/GADPH).</p></sec><sec id="sec3dot12-pharmaceuticals-14-00111"><title>3.12. Determination of Doxorubicin Accumulation </title><p>In order to evaluate the effects of <italic>E. intisy</italic> EO on intracellular accumulation of doxorubicin in HL-60R cell line, the cells were cultured in 24-well plates at a density of 1 &#x000d7; 10<sup>5</sup> cells per well. After 24 h, the cells were treated with <italic>E. intisy</italic> EO 15 &#x003bc;g/mL or verapamil 10 &#x003bc;M. After 24 h of incubation doxorubicin 1 &#x003bc;g/mL has been added for different time: 30min, 1h and 2h. Subsequently, the cells were washed twice with PBS and then resuspended in 400 &#x003bc;L PBS for doxorubicin fluorescence intensity measurement by flow cytometry using a FACSAria III instrument (Becton Dickinson, Mountain View, CA, USA). The results are presented as percentage of fluorescence intensity relative to control (means &#x000b1; SE of three experiments).</p></sec><sec id="sec3dot13-pharmaceuticals-14-00111"><title>3.13. P-gp ATPase Activity Determination</title><p>P-gp ATPase activity was performed with Pgp-Glo&#x02122; Assay Systems (Promega, Madison, WI, USA) following manufacturer&#x02019;s instructions. Different concentrations of <italic>E. intisy</italic> EO (test compound, TC) were added to a 96-well white plate in duplicate and incubated with recombinant human P-gp membranes. No treatment control (NT) with only Pgp-GLO assay buffer was used to provide a measure of unregulated ATPase activity, while Na<sub>3</sub>VO<sub>4</sub> (0.25 mM) was used as the selective inhibitor of P-gp ATPase activity and provides a measure of P-gp-independent ATPase activity. Verapamil (0.5 mM) is a P-gp substrate that stimulates P-gp ATPase activity and serves as a positive control for drug stimulation of P-gp ATPase activity. We also performed an ATP Standards curve as internal control, to verify the correct execution of the assay, and another control with DMSO (equivalent amount of higher concentration of <italic>E. intisy</italic> EO). MgATP (5 mM) was added to initiate the ATPase activity. After 40 min incubation at 37 &#x000b0;C, the reaction was stopped with 50 &#x003bc;L ATPase Detection Reagent and then incubated for 20 min at room temperature. Luminescence was measured using a GLOMAX Multidetection System (Promega). We calculated &#x00394;RLU<sub>basal</sub> that reflects basal P-gp ATPase activity as the difference between the average luminescent signals from Na<sub>3</sub>VO<sub>4</sub>-treated samples (RLU<sub>Na3VO4</sub>) and untreated (NT) samples (RLU<sub>NT</sub>). After, we calculated &#x00394;RLU<sub>TC</sub> that reflects P-gp ATPase activity in the presence of a test compound, as the difference between the average luminescent signals from Na<sub>3</sub>VO<sub>4</sub>-treated samples (RLU<sub>Na3VO4</sub>) and test compound-treated samples (RLU<sub>TC</sub>). The data were presented as change in luminescence (&#x00394;RLU). To confirm that the EO acts like the verapamil, we examined its inhibitory effects against a verapamil-stimulated P-gp ATPase activity; in this case verapamil is added in the TC wells, and the results presented as RLU produced by EO on stimulated P-gp.</p></sec><sec id="sec3dot14-pharmaceuticals-14-00111"><title>3.14. Statistical Analysis</title><p>The results are given as means &#x000b1; standard error (SE). Statistical analysis was carried out according to Poma et al. [<xref rid="B7-pharmaceuticals-14-00111" ref-type="bibr">7</xref>] by analysis of variance (one-way ANOVA) followed by Tukey&#x02019;s test. Statistica ver. 12 (StatSoft Inc., Oklahoma City, USA, 1984&#x02013;2014) was used as software for the analyses.</p></sec></sec><sec sec-type="conclusions" id="sec4-pharmaceuticals-14-00111"><title>4. Conclusions</title><p>Numerous pump inhibitors that have been produced (E.G. verapamil) are characterized by significant toxicities that reduce their use in therapy. <italic>E. intisy</italic> EO seems to have several potentialities with a very low toxicity. Our results suggest that <italic>E. intisy</italic> EO might; (i) be a stimulator of ATP-dependent drug efflux transporter; (ii) act as substrate for transport by P-gp that stimulates P-gp ATPase activity; (iii) lead to the inhibition of P-gp efflux function; (iv) reduce the expression of P-gp through NF-&#x003ba;B modulation. In fact, even though EO has a low effect on cell death, its multiple actions on P-gp enhance the antitumor effects of doxorubicin. EOs could be active in several types of cancer but their mechanism of action is complex due to the presence of several secondary metabolites. Further studies are planned to investigate the putative compounds involved in P-gp modulation among the most abundant in <italic>E. intisy</italic> EO. These compounds, or the whole EO, could be used as an adjuvant in anticancer therapy to overcome multidrug resistance. Further investigations are needed to study the pharmacokinetics of the EO.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank the Director of the Botanical Garden (University of Palermo), Rosario Schicchi, for allowing access to the living collections. Determination of doxorubicin accumulation were provided by ATeN center (University of Palermo, Italy).</p></ack><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><app-group><app id="app1-pharmaceuticals-14-00111"><title>Supplementary Materials</title><p>The following are available online at <uri xlink:href="https://www.mdpi.com/1424-8247/14/2/111/s1">https://www.mdpi.com/1424-8247/14/2/111/s1</uri>, Figure S1: GC-MS chromatogram of the essential oil of <italic>E. intisy</italic>. The peaks corresponding to relevant (&#x0003e;2%) and not identified (unknown) compounds are indicated, Figure S2: Induction of cell death by <italic>E. intisy</italic> essential oil and doxorubicin in HL-60R cells. Representative example of flow cytometry analysis of apoptosis in HL-60R cells treated for 48 h with 25 &#x003bc;g/mL of <italic>E. intisy</italic> essential oil and different concentrations of doxorubicin, either alone or in combination. The profiles of propidium iodide stained DNA are shown. The percentages of the events accumulated in the preG0&#x02013;G1 position are indicated in each panel.</p><supplementary-material content-type="local-data" id="pharmaceuticals-14-00111-s001"><media xlink:href="pharmaceuticals-14-00111-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, M.S. and M.N.; Data curation, S.R., M.T., P.P. and M.L.; Formal analysis, M.S., M.N., M.T., P.P., M.L., A.V.R. and S.R.; Funding acquisition, M.N.; Investigation, P.P. and M.L.; Methodology, M.N., M.T., P.P. and M.L.; Project administration, M.S. and M.N.; Resources, M.L.; Software, M.T. and S.R.; Supervision, M.S., M.N., P.P.; Validation, S.R. and A.V.R.; Visualization, A.V.R.; Writing&#x02014;original draft, M.S., M.N., M.T., P.P. and A.V.R.; Writing&#x02014;review and editing, M.S., M.N. and M.L. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This work was partially financed by PJ_AUTF_160829_D15 to Monica Notarbartolo.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceuticals-14-00111"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaye</surname><given-names>S.B.</given-names></name></person-group><article-title>The multidrug resistance phenotype</article-title><source>Br. J. Cancer</source><year>1988</year><volume>58</volume><fpage>691</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1038/bjc.1988.291</pub-id><?supplied-pmid 3066393?><pub-id pub-id-type="pmid">3066393</pub-id></element-citation></ref><ref id="B2-pharmaceuticals-14-00111"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juliano</surname><given-names>R.</given-names></name><name><surname>Ling</surname><given-names>V.</given-names></name></person-group><article-title>A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants</article-title><source>Biochim. Biophys. Acta</source><year>1976</year><volume>455</volume><fpage>152</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1016/0005-2736(76)90160-7</pub-id><pub-id pub-id-type="pmid">990323</pub-id></element-citation></ref><ref id="B3-pharmaceuticals-14-00111"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dewanjee</surname><given-names>S.</given-names></name><name><surname>Dua</surname><given-names>T.K.</given-names></name><name><surname>Bhattacharjee</surname><given-names>N.</given-names></name><name><surname>Das</surname><given-names>A.</given-names></name><name><surname>Gangopadhyay</surname><given-names>M.</given-names></name><name><surname>Khanra</surname><given-names>R.</given-names></name><name><surname>Joardar</surname><given-names>S.</given-names></name><name><surname>Riaz</surname><given-names>M.</given-names></name><name><surname>De Feo</surname><given-names>V.</given-names></name><name><surname>Zia-Ul-Haq</surname><given-names>M.</given-names></name></person-group><article-title>Natural Products as Alternative Choices for P-Glycoprotein (P-gp) Inhibition</article-title><source>Molecules</source><year>2017</year><volume>22</volume><elocation-id>871</elocation-id><pub-id pub-id-type="doi">10.3390/molecules22060871</pub-id><?supplied-pmid 28587082?><pub-id pub-id-type="pmid">28587082</pub-id></element-citation></ref><ref id="B4-pharmaceuticals-14-00111"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mollazadeha</surname><given-names>S.</given-names></name><name><surname>Sahebkarb</surname><given-names>A.</given-names></name><name><surname>Hadizadeha</surname><given-names>F.</given-names></name><name><surname>Behravanb</surname><given-names>J.</given-names></name><name><surname>Arabzadeh</surname><given-names>S.</given-names></name></person-group><article-title>Structural and functional aspects of P-glycoprotein and its inhibitors</article-title><source>Life Sci.</source><year>2018</year><volume>214</volume><fpage>118</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2018.10.048</pub-id><?supplied-pmid 30449449?><pub-id pub-id-type="pmid">30449449</pub-id></element-citation></ref><ref id="B5-pharmaceuticals-14-00111"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zito</surname><given-names>P.</given-names></name><name><surname>Labbozzetta</surname><given-names>M.</given-names></name><name><surname>Notarbartolo</surname><given-names>M.</given-names></name><name><surname>Sajeva</surname><given-names>M.</given-names></name><name><surname>Poma</surname><given-names>P.</given-names></name></person-group><article-title>Essential oil of <italic>Cyphostemma juttae</italic> (Vitaceae): Chemical composition and antitumor mechanism in triple negative breast cancer cells</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><elocation-id>e0214594</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0214594</pub-id><?supplied-pmid 30921428?><pub-id pub-id-type="pmid">30921428</pub-id></element-citation></ref><ref id="B6-pharmaceuticals-14-00111"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poma</surname><given-names>P.</given-names></name><name><surname>Labbozzetta</surname><given-names>M.</given-names></name><name><surname>McCubrey</surname><given-names>J.A.</given-names></name><name><surname>Ramarosandratana</surname><given-names>A.V.</given-names></name><name><surname>Sajeva</surname><given-names>M.</given-names></name><name><surname>Zito</surname><given-names>P.</given-names></name><name><surname>Notarbartolo</surname><given-names>M.</given-names></name></person-group><article-title>Antitumor mechanism of the essential oils from two succulent plants in multidrug resistance Leukemia Cell</article-title><source>Pharmaceuticals</source><year>2019</year><volume>12</volume><elocation-id>124</elocation-id><pub-id pub-id-type="doi">10.3390/ph12030124</pub-id></element-citation></ref><ref id="B7-pharmaceuticals-14-00111"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poma</surname><given-names>P.</given-names></name><name><surname>Labbozzetta</surname><given-names>M.</given-names></name><name><surname>Zito</surname><given-names>P.</given-names></name><name><surname>Alduina</surname><given-names>R.</given-names></name><name><surname>Ramarosandratana</surname><given-names>A.V.</given-names></name><name><surname>Bruno</surname><given-names>M.</given-names></name><name><surname>Rosselli</surname><given-names>S.</given-names></name><name><surname>Sajeva</surname><given-names>M.</given-names></name><name><surname>Notarbartolo</surname><given-names>M.</given-names></name></person-group><article-title>Essential Oil Composition of <italic>Alluaudia procera</italic> and in Vitro Biological Activity on Two Drug-Resistant Models</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>2871</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24162871</pub-id></element-citation></ref><ref id="B8-pharmaceuticals-14-00111"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrell</surname><given-names>J.S.</given-names></name><name><surname>Dodsworth</surname><given-names>S.</given-names></name><name><surname>Forest</surname><given-names>F.</given-names></name><name><surname>P&#x000e9;rez-Escobar</surname><given-names>O.A.</given-names></name><name><surname>Lee</surname><given-names>M.A.</given-names></name><name><surname>Mattana</surname><given-names>E.</given-names></name><name><surname>Stevenson</surname><given-names>P.C.</given-names></name><name><surname>Howes</surname><given-names>M.-J.R.</given-names></name><name><surname>Pritchard</surname><given-names>H.W.</given-names></name><name><surname>Ballesteros</surname><given-names>D.</given-names></name><etal/></person-group><article-title>The climatic challenge: Which plants will people use in the next century?</article-title><source>Environ. Exp. Bot.</source><year>2019</year><volume>170</volume><fpage>103872</fpage><pub-id pub-id-type="doi">10.1016/j.envexpbot.2019.103872</pub-id></element-citation></ref><ref id="B9-pharmaceuticals-14-00111"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grace</surname><given-names>O.M.</given-names></name></person-group><article-title>Succulent plant diversity as natural capital</article-title><source>Plants People Planet</source><year>2019</year><volume>1</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1002/ppp3.25</pub-id></element-citation></ref><ref id="B10-pharmaceuticals-14-00111"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harlev</surname><given-names>E.</given-names></name><name><surname>Nevo</surname><given-names>E.</given-names></name><name><surname>Mirsky</surname><given-names>N.</given-names></name><name><surname>Ofir</surname><given-names>R.</given-names></name></person-group><article-title>Antidiabetic attributes of desert and steppic plants: A review</article-title><source>Planta Med.</source><year>2013</year><volume>79</volume><fpage>425</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1055/s-0032-1328331</pub-id><pub-id pub-id-type="pmid">23539351</pub-id></element-citation></ref><ref id="B11-pharmaceuticals-14-00111"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizvi</surname><given-names>M.A.</given-names></name><name><surname>Saeed</surname><given-names>A.</given-names></name></person-group><article-title>Medicinal plants of arid zones: Utilization, cultivation and conservation</article-title><source>Hamdard Med.</source><year>2013</year><volume>56</volume><fpage>53</fpage><lpage>80</lpage></element-citation></ref><ref id="B12-pharmaceuticals-14-00111"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dongling</surname><given-names>L.</given-names></name><name><surname>Yinquan</surname><given-names>W.</given-names></name><name><surname>Ling</surname><given-names>T.</given-names></name></person-group><article-title>Medicinal Plants in the Northwestern China and Their Medicinal Uses</article-title><source>Aromat. Med. Plants Back Nat.</source><year>2017</year><fpage>215</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.5772/66739</pub-id></element-citation></ref><ref id="B13-pharmaceuticals-14-00111"><label>13.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Najjaa</surname><given-names>H.</given-names></name><name><surname>Ben Arfa</surname><given-names>A.</given-names></name><name><surname>M&#x000e1;th&#x000e9;</surname><given-names>&#x000c1;.</given-names></name><name><surname>Neffati</surname><given-names>M.</given-names></name></person-group><article-title>Aromatic and medicinal plants of Tunisian arid and desert zone used in traditional medicine, for drug discovery and biotechnological applications</article-title><source>Medicinal and Aromatic Plants of the World&#x02014;Africa</source><person-group person-group-type="editor"><name><surname>Neffati</surname><given-names>M.</given-names></name><name><surname>Najjaa</surname><given-names>H.</given-names></name><name><surname>Arfa</surname><given-names>A.B.</given-names></name><name><surname>M&#x000e1;th&#x000e9;</surname><given-names>&#x000c1;.</given-names></name></person-group><publisher-name>Springer Science + Business Media</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2017</year><volume>Volume 3</volume><fpage>157</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1007/978-94-024-1120-1_8</pub-id></element-citation></ref><ref id="B14-pharmaceuticals-14-00111"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frodin</surname><given-names>D.G.</given-names></name></person-group><article-title>History and concepts of big plant genera</article-title><source>Taxon</source><year>2004</year><volume>53</volume><fpage>753</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.2307/4135449</pub-id></element-citation></ref><ref id="B15-pharmaceuticals-14-00111"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horn</surname><given-names>J.W.</given-names></name><name><surname>van Ee</surname><given-names>B.W.</given-names></name><name><surname>Morawetz</surname><given-names>J.J.</given-names></name><name><surname>Riina</surname><given-names>R.</given-names></name><name><surname>Steinmann</surname><given-names>V.W.</given-names></name><name><surname>Berry</surname><given-names>P.E.</given-names></name><name><surname>Wurdack</surname><given-names>K.J.</given-names></name></person-group><article-title>Phylogenetics and the evolution of major structural characters in the giant genus <italic>Euphorbia</italic> L. (Euphorbiaceae)</article-title><source>Mol. Phylogenet. Evol.</source><year>2012</year><volume>63</volume><fpage>305</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1016/j.ympev.2011.12.022</pub-id><?supplied-pmid 22273597?><pub-id pub-id-type="pmid">22273597</pub-id></element-citation></ref><ref id="B16-pharmaceuticals-14-00111"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernst</surname><given-names>M.</given-names></name><name><surname>Nothias</surname><given-names>L.-F.</given-names></name><name><surname>van der Hooft</surname><given-names>J.J.J.</given-names></name><name><surname>Silva</surname><given-names>R.R.</given-names></name><name><surname>Saslis-Lagoudakis</surname><given-names>C.H.</given-names></name><name><surname>Grace</surname><given-names>O.M.</given-names></name><name><surname>Martinez-Swatson</surname><given-names>K.</given-names></name><name><surname>Hassemer</surname><given-names>G.</given-names></name><name><surname>Funez</surname><given-names>L.A.</given-names></name><name><surname>Simonsen</surname><given-names>H.T.</given-names></name><etal/></person-group><article-title>Assessing specialized metabolite diversity in the cosmopolitan plant genus <italic>Euphorbia</italic> L.</article-title><source>Front. Plant. Sci.</source><year>2019</year><volume>10</volume><fpage>846</fpage><pub-id pub-id-type="doi">10.3389/fpls.2019.00846</pub-id><?supplied-pmid 31333695?><pub-id pub-id-type="pmid">31333695</pub-id></element-citation></ref><ref id="B17-pharmaceuticals-14-00111"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kemboi</surname><given-names>D.</given-names></name><name><surname>Peter</surname><given-names>X.</given-names></name><name><surname>Langat</surname><given-names>M.</given-names></name><name><surname>Tembu</surname><given-names>J.</given-names></name></person-group><article-title>A Review of the Ethnomedicinal Uses, Biological Activities, and Triterpenoids of <italic>Euphorbia</italic> Species</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>4019</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25174019</pub-id><?supplied-pmid 32899130?><pub-id pub-id-type="pmid">32899130</pub-id></element-citation></ref><ref id="B18-pharmaceuticals-14-00111"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernst</surname><given-names>M.</given-names></name><name><surname>Grace</surname><given-names>O.M.</given-names></name><name><surname>Saslis-Lagoudakis</surname><given-names>C.H.</given-names></name><name><surname>Nilsson</surname><given-names>N.</given-names></name><name><surname>Simonsen</surname><given-names>H.T.</given-names></name><name><surname>R&#x000f8;nsted</surname><given-names>N.</given-names></name></person-group><article-title>Global medicinal uses of <italic>Euphorbia</italic> L. (Euphorbiaceae)</article-title><source>J. Ethnopharmacol.</source><year>2015</year><volume>176</volume><fpage>90</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2015.10.025</pub-id><pub-id pub-id-type="pmid">26485050</pub-id></element-citation></ref><ref id="B19-pharmaceuticals-14-00111"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Q.-W.</given-names></name><name><surname>Su</surname><given-names>X.-H.</given-names></name><name><surname>Kiyota</surname><given-names>H.</given-names></name></person-group><article-title>Chemical and pharmacological research of the plants in genus <italic>Euphorbia</italic></article-title><source>Chem. Rev.</source><year>2008</year><volume>108</volume><fpage>4295</fpage><lpage>4327</lpage><pub-id pub-id-type="doi">10.1021/cr078350s</pub-id><pub-id pub-id-type="pmid">18817355</pub-id></element-citation></ref><ref id="B20-pharmaceuticals-14-00111"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mwine</surname><given-names>J.T.</given-names></name><name><surname>Van Damme</surname><given-names>P.</given-names></name></person-group><article-title>Why do Euphorbiaceae tick as medicinal plants? A review of Euphorbiaceae family and its medicinal features</article-title><source>J. Med. Plants Res.</source><year>2011</year><volume>5</volume><fpage>652</fpage><lpage>662</lpage></element-citation></ref><ref id="B21-pharmaceuticals-14-00111"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salehi</surname><given-names>B.</given-names></name><name><surname>Iriti</surname><given-names>M.</given-names></name><name><surname>Vitalini</surname><given-names>S.</given-names></name><name><surname>Antolak</surname><given-names>H.</given-names></name><name><surname>Pawlikowska</surname><given-names>E.</given-names></name><name><surname>Kr&#x00119;giel</surname><given-names>D.</given-names></name><name><surname>Sharifi-Rad</surname><given-names>J.</given-names></name><name><surname>Oyeleye</surname><given-names>S.I.</given-names></name><name><surname>Ademiluyi</surname><given-names>A.O.</given-names></name><name><surname>Czopek</surname><given-names>K.</given-names></name><etal/></person-group><article-title><italic>Euphorbia</italic>-derived natural products with potential for use in health maintenance</article-title><source>Biomolecules</source><year>2019</year><volume>9</volume><elocation-id>337</elocation-id><pub-id pub-id-type="doi">10.3390/biom9080337</pub-id></element-citation></ref><ref id="B22-pharmaceuticals-14-00111"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duarte</surname><given-names>N.</given-names></name><name><surname>Ramalhete</surname><given-names>C.</given-names></name><name><surname>Varga</surname><given-names>A.</given-names></name><name><surname>Moln&#x000e1;r</surname><given-names>J.</given-names></name><name><surname>Ferreira</surname><given-names>M.-J.U.</given-names></name></person-group><article-title>Multidrug resistance modulation and apoptosis induction of cancer cells by terpenic compounds isolated from <italic>Euphorbia</italic> species</article-title><source>Anticancer Res.</source><year>2009</year><volume>29</volume><fpage>4467</fpage><lpage>4472</lpage><?supplied-pmid 20032393?><pub-id pub-id-type="pmid">20032393</pub-id></element-citation></ref><ref id="B23-pharmaceuticals-14-00111"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aleksandrov</surname><given-names>M.</given-names></name><name><surname>Maksimova</surname><given-names>V.</given-names></name><name><surname>Koleva Gudeva</surname><given-names>L.</given-names></name></person-group><article-title>Review of the anticancer and cytotoxic activity of some species from genus <italic>Euphorbia</italic></article-title><source>Agric. Conspec. Sci.</source><year>2018</year><volume>84</volume><fpage>1</fpage><lpage>5</lpage></element-citation></ref><ref id="B24-pharmaceuticals-14-00111"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wongrakpanich</surname><given-names>A.</given-names></name><name><surname>Charoensuksai</surname><given-names>P.</given-names></name></person-group><article-title>Induction of apoptosis in cancer cells by plants in the genus <italic>Euphorbia</italic></article-title><source>Thai Bull. Pharm. Sci.</source><year>2018</year><volume>13</volume><fpage>1</fpage><lpage>11</lpage></element-citation></ref><ref id="B25-pharmaceuticals-14-00111"><label>25.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>K&#x000fa;sz</surname><given-names>N.</given-names></name></person-group><article-title>Isolation and Structure Elucidation of Bioactive Compounds from <italic>Euphorbia</italic> Species</article-title><source>Ph.D. Thesis</source><publisher-name>University of Szeged</publisher-name><publisher-loc>Szeged, Hungary</publisher-loc><year>2020</year><size units="pages">55p</size></element-citation></ref><ref id="B26-pharmaceuticals-14-00111"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fokialakis</surname><given-names>N.</given-names></name><name><surname>Melliou</surname><given-names>E.</given-names></name><name><surname>Magiatis</surname><given-names>P.</given-names></name><name><surname>Harvala</surname><given-names>C.</given-names></name><name><surname>Mitaku</surname><given-names>S.</given-names></name></person-group><article-title>Composition of the steam volatiles of six <italic>Euphorbia</italic> spp. from Greece</article-title><source>Flavour Fragr. J.</source><year>2003</year><volume>18</volume><fpage>39</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1002/ffj.1148</pub-id></element-citation></ref><ref id="B27-pharmaceuticals-14-00111"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feizbakhsh</surname><given-names>A.</given-names></name><name><surname>Bighdeli</surname><given-names>M.</given-names></name><name><surname>Tehrani</surname><given-names>M.S.</given-names></name><name><surname>Rustaiyan</surname><given-names>A.</given-names></name></person-group><article-title>Chemical constituents of the essential oil of <italic>Euphorbia teheranica</italic> Boiss., a species endemic to Iran</article-title><source>J. Essent. Oil Res.</source><year>2004</year><volume>16</volume><fpage>40</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1080/10412905.2004.9698647</pub-id></element-citation></ref><ref id="B28-pharmaceuticals-14-00111"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rojas</surname><given-names>J.</given-names></name><name><surname>Baldovino</surname><given-names>S.</given-names></name><name><surname>Vizcaya</surname><given-names>M.</given-names></name><name><surname>Rojas</surname><given-names>L.B.</given-names></name><name><surname>Morales</surname><given-names>A.</given-names></name></person-group><article-title>The chemical composition of the essential oils of <italic>Euphorbia caracasana</italic> and <italic>E. cotinifolia</italic> (Euphorbiaceae) from Venezuela</article-title><source>Nat. Prod. Commun.</source><year>2009</year><volume>4</volume><fpage>571</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1177/1934578X0900400426</pub-id><?supplied-pmid 19476008?><pub-id pub-id-type="pmid">19476008</pub-id></element-citation></ref><ref id="B29-pharmaceuticals-14-00111"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elshamy</surname><given-names>A.I.</given-names></name><name><surname>Abd El-Gawad</surname><given-names>A.M.</given-names></name><name><surname>El Gendy</surname><given-names>A.N.G.</given-names></name><name><surname>Assaeed</surname><given-names>A.M.</given-names></name></person-group><article-title>Chemical characterization of <italic>Euphorbia heterophylla</italic> L. essential oils and their antioxidant activity and allelopathic potential on <italic>Cenchrus echinatus</italic> L</article-title><source>Chem. Biodivers.</source><year>2019</year><volume>16</volume><fpage>E1900051</fpage><pub-id pub-id-type="doi">10.1002/cbdv.201900051</pub-id><pub-id pub-id-type="pmid">30875445</pub-id></element-citation></ref><ref id="B30-pharmaceuticals-14-00111"><label>30.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Haevermans</surname><given-names>T.</given-names></name></person-group><article-title>Le genre <italic>Euphorbia</italic> &#x000e0; Madagascar: Phylog&#x000e9;nie Mol&#x000e9;culaire et Syst&#x000e9;matique</article-title><source>Ph.D. Thesis</source><publisher-name>MNHN</publisher-name><publisher-loc>Paris, France</publisher-loc><year>2003</year></element-citation></ref><ref id="B31-pharmaceuticals-14-00111"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rafidison</surname><given-names>V.</given-names></name><name><surname>Ratsimandresy</surname><given-names>F.</given-names></name><name><surname>Rakotondrajaona</surname><given-names>R.</given-names></name><name><surname>Rasamison</surname><given-names>V.</given-names></name><name><surname>Rakotoarisoa</surname><given-names>M.</given-names></name><name><surname>Rakotondrafara</surname><given-names>A.</given-names></name><name><surname>Rakotonandrasana</surname><given-names>S.R.</given-names></name></person-group><article-title>Synth&#x000e8;se et analyse de donn&#x000e9;es sur les inventaires de plantes m&#x000e9;dicinales de Madagascar</article-title><source>Ethnobot. Res. Appl.</source><year>2019</year><volume>18</volume><fpage>40</fpage><pub-id pub-id-type="doi">10.32859/era.18.40.1-19</pub-id></element-citation></ref><ref id="B32-pharmaceuticals-14-00111"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>J.C.</given-names></name><name><surname>Tsirahamba</surname><given-names>S.</given-names></name></person-group><article-title>Forests and thorns: Conditions of change affecting Mahafale pastoralists in Southwestern Madagascar</article-title><source>Conserv. Soc.</source><year>2006</year><volume>4</volume><fpage>231</fpage><lpage>261</lpage></element-citation></ref><ref id="B33-pharmaceuticals-14-00111"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swingle</surname><given-names>C.F.</given-names></name></person-group><article-title>The anatomy of <italic>Euphorbia intisy</italic></article-title><source>J. Agric. Res.</source><year>1930</year><volume>40</volume><fpage>615</fpage><lpage>625</lpage></element-citation></ref><ref id="B34-pharmaceuticals-14-00111"><label>34.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Perrier de la Bathie</surname><given-names>H.</given-names></name></person-group><article-title>Les plantes &#x000e0; caoutchouc de Madagascar valeur et possibilit&#x000e9; de leur culture</article-title><source>Revue Internationale de Botanique Appliqu&#x000e9;e et D&#x02019;agriculture Tropicale, 29e Ann&#x000e9;e, Bulletin n&#x000b0;315&#x02013;316</source><publisher-name>Janvier-F&#x000e9;vrier</publisher-name><publisher-loc>Paris, France</publisher-loc><year>1949</year><volume>Volume 26</volume><fpage>17</fpage><lpage>20</lpage><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.persee.fr/doc/jatba_0370-5412_1949_num_29_315_6199">https://www.persee.fr/doc/jatba_0370-5412_1949_num_29_315_6199</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-10-22">(accessed on 22 October 2019)</date-in-citation><pub-id pub-id-type="doi">10.3406/jatba.1949.6199</pub-id></element-citation></ref><ref id="B35-pharmaceuticals-14-00111"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decary</surname><given-names>R.</given-names></name></person-group><article-title>Les emplois des Euphorbiac&#x000e9;es malgaches</article-title><source>J. Agric. Trop. Bot. Appl. Ao&#x000fb;t Sept.</source><year>1966</year><volume>13</volume><fpage>467</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.3406/jatba.1966.2896</pub-id></element-citation></ref><ref id="B36-pharmaceuticals-14-00111"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vacher</surname><given-names>C.</given-names></name></person-group><article-title>Le caoutchouc dans l&#x02019;extr&#x000ea;me sud malgache</article-title><source>Bull. &#x000c9;con. Madag. D&#x000e9;pend.</source><year>1907</year><volume>7</volume><fpage>128</fpage><lpage>141</lpage></element-citation></ref><ref id="B37-pharmaceuticals-14-00111"><label>37.</label><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Haevermans</surname><given-names>T.</given-names></name></person-group><article-title>Euphorbia Intisy. The IUCN Red List of Threatened Species 2019: E.T44367A124142437</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https//www.iucnredlist.org">https//www.iucnredlist.org</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-10-19">(accessed on 19 October 2020)</date-in-citation></element-citation></ref><ref id="B38-pharmaceuticals-14-00111"><label>38.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>R.P.</given-names></name></person-group><source>Identification of Essential oil Components by Gas Chromatography/Mass Spectrometry</source><publisher-name>Allured Publishing Corporation</publisher-name><publisher-loc>Carol Stream, IL, USA</publisher-loc><year>2007</year><fpage>456</fpage></element-citation></ref><ref id="B39-pharmaceuticals-14-00111"><label>39.</label><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>El-Sayed</surname><given-names>A.M.</given-names></name></person-group><article-title>The Pherobase: Database of Insect Pheromones and Semiochemicals</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.pherobase.com/">http://www. pherobase.com/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-09-30">(accessed on 30 September 2020)</date-in-citation></element-citation></ref><ref id="B40-pharmaceuticals-14-00111"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mize</surname><given-names>C.E.</given-names></name><name><surname>Steinberg</surname><given-names>D.</given-names></name><name><surname>Avigan</surname><given-names>J.</given-names></name><name><surname>Fales</surname><given-names>H.M.</given-names></name></person-group><article-title>A pathway for oxidative degradation of phytanic acid in mammals</article-title><source>Biochem. Biophys. Res. Commun.</source><year>1966</year><volume>25</volume><fpage>359</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1016/0006-291X(66)90786-8</pub-id><pub-id pub-id-type="pmid">5972842</pub-id></element-citation></ref><ref id="B41-pharmaceuticals-14-00111"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>D.</given-names></name><name><surname>Avigan</surname><given-names>J.</given-names></name><name><surname>Mize</surname><given-names>C.E.</given-names></name><name><surname>Baxter</surname><given-names>J.H.</given-names></name><name><surname>Cammermeyer</surname><given-names>J.</given-names></name><name><surname>Fales</surname><given-names>H.M.</given-names></name><name><surname>Highet</surname><given-names>P.F.</given-names></name></person-group><article-title>Effects of dietary phytol and phytanic acid in animals</article-title><source>J. Lipid Res.</source><year>1966</year><volume>7</volume><fpage>684</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1016/S0022-2275(20)39251-8</pub-id><pub-id pub-id-type="pmid">4165840</pub-id></element-citation></ref><ref id="B42-pharmaceuticals-14-00111"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Islam</surname><given-names>M.T.</given-names></name><name><surname>Ali</surname><given-names>E.S.</given-names></name><name><surname>Uddin</surname><given-names>S.J.</given-names></name><name><surname>Shaw</surname><given-names>S.</given-names></name><name><surname>Islam</surname><given-names>M.A.</given-names></name><name><surname>Ahmed</surname><given-names>M.I.</given-names></name><name><surname>Billah</surname><given-names>M.M.</given-names></name></person-group><article-title>Phytol: A review of biomedical activities</article-title><source>Food Chem. Toxicol.</source><year>2018</year><volume>121</volume><fpage>82</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2018.08.032</pub-id><pub-id pub-id-type="pmid">30130593</pub-id></element-citation></ref><ref id="B43-pharmaceuticals-14-00111"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robbins</surname><given-names>W.E.</given-names></name><name><surname>Kaplanis</surname><given-names>J.N.</given-names></name><name><surname>Thompson</surname><given-names>M.J.</given-names></name><name><surname>Shortino</surname><given-names>T.J.</given-names></name><name><surname>Cohen</surname><given-names>C.F.</given-names></name><name><surname>Joyner</surname><given-names>S.C.</given-names></name></person-group><article-title>Ecdysones and analogs: Effects on development and reproduction of insects</article-title><source>Science</source><year>1968</year><volume>161</volume><fpage>1158</fpage><lpage>1160</lpage><pub-id pub-id-type="doi">10.1126/science.161.3846.1158</pub-id><pub-id pub-id-type="pmid">17812297</pub-id></element-citation></ref><ref id="B44-pharmaceuticals-14-00111"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J.E.</given-names></name><name><surname>Kim</surname><given-names>J.M.</given-names></name><name><surname>Lee</surname><given-names>N.H.</given-names></name><name><surname>Yang</surname><given-names>J.Y.</given-names></name><name><surname>Lee</surname><given-names>H.S.</given-names></name></person-group><article-title>Acaricidal and insecticidal activities of essential oils against a stored-food mite and stored-grain insects</article-title><source>J. Food Prot.</source><year>2016</year><volume>79</volume><fpage>174</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.4315/0362-028X.JFP-15-109</pub-id><pub-id pub-id-type="pmid">26735047</pub-id></element-citation></ref><ref id="B45-pharmaceuticals-14-00111"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x00105;browska</surname><given-names>P.</given-names></name><name><surname>Boland</surname><given-names>W.</given-names></name></person-group><article-title>iso-OPDA: An Early Precursor of cis-Jasmone in Plants?</article-title><source>Chembiochem</source><year>2007</year><volume>8</volume><fpage>2281</fpage><lpage>2285</lpage><pub-id pub-id-type="doi">10.1002/cbic.200700464</pub-id><pub-id pub-id-type="pmid">18033720</pub-id></element-citation></ref><ref id="B46-pharmaceuticals-14-00111"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radulovi&#x00107;</surname><given-names>N.</given-names></name><name><surname>Stojanovi&#x00107;</surname><given-names>G.</given-names></name><name><surname>Pali&#x00107;</surname><given-names>R.</given-names></name></person-group><article-title>Composition and antimicrobial activity of <italic>Equisetum arvense</italic> L. essential oil</article-title><source>Phytother. Res.</source><year>2006</year><volume>20</volume><fpage>85</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1002/ptr.1815</pub-id><pub-id pub-id-type="pmid">16397851</pub-id></element-citation></ref><ref id="B47-pharmaceuticals-14-00111"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duru</surname><given-names>M.E.</given-names></name><name><surname>Cakir</surname><given-names>A.</given-names></name><name><surname>Kordali</surname><given-names>S.</given-names></name><name><surname>Zengin</surname><given-names>H.</given-names></name><name><surname>Harmandar</surname><given-names>M.</given-names></name><name><surname>Izumi</surname><given-names>S.</given-names></name><name><surname>Hirata</surname><given-names>T.</given-names></name></person-group><article-title>Chemical composition and antifungal properties of essential oils of three Pistacia species</article-title><source>Fitoterapia</source><year>2003</year><volume>74</volume><fpage>170</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/S0367-326X(02)00318-0</pub-id><pub-id pub-id-type="pmid">12628418</pub-id></element-citation></ref><ref id="B48-pharmaceuticals-14-00111"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Notarbartolo</surname><given-names>M.</given-names></name><name><surname>Cervello</surname><given-names>M.</given-names></name><name><surname>Dusonchet</surname><given-names>L.</given-names></name><name><surname>Cusimano</surname><given-names>A.</given-names></name><name><surname>D&#x02019;Alessandro</surname><given-names>N.</given-names></name></person-group><article-title>Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins)</article-title><source>Cancer Lett.</source><year>2002</year><volume>180</volume><fpage>91</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/S0304-3835(01)00834-5</pub-id><pub-id pub-id-type="pmid">11911975</pub-id></element-citation></ref><ref id="B49-pharmaceuticals-14-00111"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fidyt</surname><given-names>K.</given-names></name><name><surname>Fiedorowicz</surname><given-names>A.</given-names></name><name><surname>Strz&#x00105;da&#x00142;a</surname><given-names>L.</given-names></name><name><surname>Szumny</surname><given-names>A.</given-names></name></person-group><article-title>&#x003b2;-caryophyllene and &#x003b2;-caryophyllene oxide&#x02014;Natural compounds of anticancer and analgesic properties</article-title><source>Cancer Med.</source><year>2016</year><volume>5</volume><fpage>3007</fpage><lpage>3017</lpage><pub-id pub-id-type="doi">10.1002/cam4.816</pub-id><?supplied-pmid 27696789?><pub-id pub-id-type="pmid">27696789</pub-id></element-citation></ref><ref id="B50-pharmaceuticals-14-00111"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Notarbartolo</surname><given-names>M.</given-names></name><name><surname>Cervello</surname><given-names>M.</given-names></name><name><surname>Poma</surname><given-names>P.</given-names></name><name><surname>Dusonchet</surname><given-names>L.</given-names></name><name><surname>Meli</surname><given-names>M.</given-names></name><name><surname>D&#x02019;Alessandro</surname><given-names>N.</given-names></name></person-group><article-title>Expression of the IAPs in multidrug resistant tumor cells</article-title><source>Oncol. Rep.</source><year>2004</year><volume>11</volume><fpage>133</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.3892/or.11.1.133</pub-id><?supplied-pmid 14654915?><pub-id pub-id-type="pmid">14654915</pub-id></element-citation></ref><ref id="B51-pharmaceuticals-14-00111"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eid</surname><given-names>S.Y.</given-names></name><name><surname>El-Readi</surname><given-names>M.Z.</given-names></name><name><surname>Eldin</surname><given-names>E.E.M.N.</given-names></name><name><surname>Fatani</surname><given-names>S.H.</given-names></name><name><surname>Wink</surname><given-names>M.</given-names></name></person-group><article-title>Influence of combinations of digitonin with selected phenolics, terpenoids, and alkaloids on the expression and activity of P-glycoprotein in leukaemia and colon cancer cells</article-title><source>Phytomedicine</source><year>2013</year><volume>21</volume><fpage>47</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2013.07.019</pub-id><?supplied-pmid 23999162?><pub-id pub-id-type="pmid">23999162</pub-id></element-citation></ref><ref id="B52-pharmaceuticals-14-00111"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wortelboer</surname><given-names>H.M.</given-names></name><name><surname>Usta</surname><given-names>M.</given-names></name><name><surname>van Zanden</surname><given-names>J.J.</given-names></name><name><surname>van Bladeren</surname><given-names>P.J.</given-names></name><name><surname>Rietjens</surname><given-names>I.M.</given-names></name><name><surname>Cnubben</surname><given-names>N.H.</given-names></name></person-group><article-title>Inhibition of multidrug resistance proteins MRP1 and MRP2 by a series of &#x003b1;, &#x003b2;-unsaturated carbonyl compounds</article-title><source>Biochem. Pharmacol.</source><year>2005</year><volume>69</volume><fpage>1879</fpage><lpage>1890</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2005.04.001</pub-id><pub-id pub-id-type="pmid">15885658</pub-id></element-citation></ref><ref id="B53-pharmaceuticals-14-00111"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valente</surname><given-names>I.</given-names></name><name><surname>Reis</surname><given-names>M.</given-names></name><name><surname>Duarte</surname><given-names>N.</given-names></name><name><surname>Serly</surname><given-names>J.</given-names></name><name><surname>Moln&#x000e1;r</surname><given-names>J.</given-names></name><name><surname>Ferreira</surname><given-names>M.J.U.</given-names></name></person-group><article-title>Jatrophane diterpenes from <italic>Euphorbia mellifera</italic> and their activity as P-glycoprotein modulators on multidrug-resistant mouse lymphoma and human colon adenocarcinoma cells</article-title><source>J. Nat. Prod.</source><year>2012</year><volume>75</volume><fpage>1915</fpage><lpage>1921</lpage><pub-id pub-id-type="doi">10.1021/np3004003</pub-id><pub-id pub-id-type="pmid">23098168</pub-id></element-citation></ref><ref id="B54-pharmaceuticals-14-00111"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madureira</surname><given-names>A.M.</given-names></name><name><surname>Gy&#x000e9;m&#x000e1;nt</surname><given-names>N.</given-names></name><name><surname>Ascenso</surname><given-names>J.R.</given-names></name><name><surname>Abreu</surname><given-names>P.M.</given-names></name><name><surname>Moln&#x000e1;r</surname><given-names>J.</given-names></name><name><surname>Ferreira</surname><given-names>M.J.U.</given-names></name></person-group><article-title>Euphoportlandols A and B, Tetracylic Diterpene Polyesters from <italic>Euphorbia portlandica</italic> and Their Anti-MDR Effects in Cancer Cells</article-title><source>J. Nat. Prod.</source><year>2006</year><volume>69</volume><fpage>950</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1021/np060046r</pub-id><pub-id pub-id-type="pmid">16792416</pub-id></element-citation></ref><ref id="B55-pharmaceuticals-14-00111"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moln&#x000e1;r</surname><given-names>J.</given-names></name><name><surname>Gy&#x000e9;m&#x000e1;nt</surname><given-names>N.</given-names></name><name><surname>Tanaka</surname><given-names>M.</given-names></name><name><surname>Hohmann</surname><given-names>J.</given-names></name><name><surname>Bergmann-Leitner</surname><given-names>E.</given-names></name><name><surname>Moln&#x000e1;r</surname><given-names>P.</given-names></name><name><surname>Deli</surname><given-names>J.</given-names></name><name><surname>Didiziapetris</surname><given-names>R.</given-names></name><name><surname>Ferreira</surname><given-names>M.J.U.</given-names></name></person-group><article-title>Inhibition of multidrug resistance of cancer cells by natural diterpenes, triterpenes and carotenoids</article-title><source>Curr. Pharm. Des.</source><year>2006</year><volume>12</volume><fpage>287</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.2174/138161206775201893</pub-id><pub-id pub-id-type="pmid">16454745</pub-id></element-citation></ref><ref id="B56-pharmaceuticals-14-00111"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neto</surname><given-names>S.</given-names></name><name><surname>Duarte</surname><given-names>N.</given-names></name><name><surname>Pedro</surname><given-names>C.</given-names></name><name><surname>Spengler</surname><given-names>G.</given-names></name><name><surname>Moln&#x000e1;r</surname><given-names>J.</given-names></name><name><surname>Ferreira</surname><given-names>M.J.U.</given-names></name></person-group><article-title>Effective MDR reversers through phytochemical study of <italic>Euphorbia boetica</italic></article-title><source>Phytochem. Anal.</source><year>2019</year><volume>30</volume><fpage>498</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1002/pca.2841</pub-id><pub-id pub-id-type="pmid">31218764</pub-id></element-citation></ref><ref id="B57-pharmaceuticals-14-00111"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reis</surname><given-names>M.A.</given-names></name><name><surname>Ahmed</surname><given-names>O.B.</given-names></name><name><surname>Spengler</surname><given-names>G.</given-names></name><name><surname>Moln&#x000e1;r</surname><given-names>J.</given-names></name><name><surname>Lage</surname><given-names>H.</given-names></name><name><surname>Ferreira</surname><given-names>M.J.U.</given-names></name></person-group><article-title>Jatrophane diterpenes and cancer multidrug resistance&#x02013;ABCB1 efflux modulation and selective cell death induction</article-title><source>Phytomedicine</source><year>2016</year><volume>23</volume><fpage>968</fpage><lpage>978</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2016.05.007</pub-id><pub-id pub-id-type="pmid">27387405</pub-id></element-citation></ref><ref id="B58-pharmaceuticals-14-00111"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zito</surname><given-names>P.</given-names></name><name><surname>Sajeva</surname><given-names>M.</given-names></name><name><surname>Bruno</surname><given-names>M.</given-names></name><name><surname>Rosselli</surname><given-names>S.</given-names></name><name><surname>Maggio</surname><given-names>A.</given-names></name><name><surname>Senatore</surname><given-names>F.</given-names></name><name><surname>Formisano</surname><given-names>C.</given-names></name></person-group><article-title>Essential oil composition of <italic>Periploca laevigata</italic> Aiton subsp. angustifolia (Labill.) Markgraf (Apocynaceae-Periplocoideae)</article-title><source>Nat. Prod. Res.</source><year>2013</year><volume>27</volume><fpage>255</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1080/14786419.2012.671319</pub-id><?supplied-pmid 22439883?><pub-id pub-id-type="pmid">22439883</pub-id></element-citation></ref><ref id="B59-pharmaceuticals-14-00111"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>T.C.</given-names></name><name><surname>Talalay</surname><given-names>P.</given-names></name></person-group><article-title>Analysis of combined drug effects: A new look at a very old problem</article-title><source>Trends Pharmacol. Sci.</source><year>1983</year><volume>4</volume><fpage>450</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1016/0165-6147(83)90490-X</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="pharmaceuticals-14-00111-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p><italic>Euphorbia intisy</italic> cultivated at the Botanical Garden of the University of Palermo (photo M. Sajeva).</p></caption><graphic xlink:href="pharmaceuticals-14-00111-g001"/></fig><fig id="pharmaceuticals-14-00111-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Cytotoxic activity of <italic>E. intisy</italic> essential oil on leukemia HL-60, HL-60R, and differentiated Caco-2 cell lines. Cells were exposed to EO for 72 h, at different concentrations and viability was assessed by MTS assay. Data are expressed as mean &#x000b1; standard error of three experiments performed in triplicate. Different letters represent significant differences (Tukey&#x02019;s test) in cytotoxic activity among the concentrations of each cell line (<italic>p</italic> &#x0003c; 0.05).</p></caption><graphic xlink:href="pharmaceuticals-14-00111-g002"/></fig><fig id="pharmaceuticals-14-00111-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Induction of cell death by <italic>E. intisy</italic> essential oil in HL-60 and HL-60R cells. Representative example of flow cytometry analysis of cell death and cell cycle in the HL-60 and HL-60R cells treated with 25 &#x003bc;g/mL of <italic>E. intisy</italic> essential oil for 24 h. The profiles of propidium iodide-stained DNA are shown. Numbers in the panels indicate the % of the events in the preG<sub>0</sub>-G<sub>1</sub> position.</p></caption><graphic xlink:href="pharmaceuticals-14-00111-g003"/></fig><fig id="pharmaceuticals-14-00111-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>NF-&#x003ba;B (p65 subunit) DNA binding capacity in nuclear extracts of HL-60 and HL-60R cells. The cells were treated for 24 h with <italic>E. intisy</italic> essential oil (25 &#x003bc;g/mL). Results (mean &#x000b1; standard error of three experiments carried out in duplicate) are expressed as arbitrary units/&#x003bc;g protein of cells nuclear extracts. Statistical differences are * <italic>p</italic> &#x0003c; 0.01 vs. control (Tukey&#x02019;s test).</p></caption><graphic xlink:href="pharmaceuticals-14-00111-g004"/></fig><fig id="pharmaceuticals-14-00111-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Genes mRNA expression levels by quantitative polymerase chain reaction in HL-60R cells. The cells were treated for 24 h with <italic>E. intisy</italic> essential oil (25 &#x003bc;g/mL). Data are expressed as mean &#x000b1; standard error of three experiments. Differences when treatments are compared to the control * <italic>p</italic> &#x0003c; 0.01 (Tukey&#x02019;s test).</p></caption><graphic xlink:href="pharmaceuticals-14-00111-g005"/></fig><fig id="pharmaceuticals-14-00111-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Western blotting analysis of the levels of Survivin, XIAP, Bcl-2, and P-gp, in HL-60R cells. The cells were treated for 24 h with <italic>E. intisy</italic> essential oil (25 &#x003bc;g/mL). On the left, the results of a representative experiment; on the right, the results expressed as mean &#x000b1; standard error of three experiments. Differences when treatments are compared to the control: ** <italic>p</italic> &#x0003c; 0.01, * <italic>p</italic> &#x0003c; 0.05 (Tukey&#x02019;s test).</p></caption><graphic xlink:href="pharmaceuticals-14-00111-g006"/></fig><fig id="pharmaceuticals-14-00111-f007" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Effects of <italic>E. intisy</italic> EO on intracellular accumulation of doxorubicin in HL-60 cell line. Representative example of flow cytometry analysis of intracellular accumulation of doxorubicin (1 &#x003bc;g/mL) after different time of incubation (30 min, 1 h and 2 h) in HL-60 cells pre-treated with 15 &#x003bc;g/mL of <italic>E. intisy</italic> essential oil or verapamil 10 &#x003bc;M for 24 h.</p></caption><graphic xlink:href="pharmaceuticals-14-00111-g007"/></fig><fig id="pharmaceuticals-14-00111-f008" orientation="portrait" position="float"><label>Figure 8</label><caption><p>Effects of <italic>E. intisy</italic> EO on intracellular accumulation of doxorubicin in HL-60R cell line. Representative example of flow cytometry analysis of intracellular accumulation of doxorubicin (1 &#x003bc;g/mL) after different time of incubation (30 min, 1 h and 2 h) in HL-60R cells pre-treated with 15 &#x003bc;g/mL of <italic>E. intisy</italic> essential oil or verapamil 10 &#x003bc;M for 24 h.</p></caption><graphic xlink:href="pharmaceuticals-14-00111-g008"/></fig><fig id="pharmaceuticals-14-00111-f009" orientation="portrait" position="float"><label>Figure 9</label><caption><p>Effects of <italic>E. intisy</italic> EO (5&#x02013;50 &#x000b5;g/mL) on P-gp basal ATPase activity. The data are expressed as fold changes of P-gp ATPase activity compared to basal one (&#x00394;RLU<sub>TC</sub>/&#x00394;RLU<sub>basal</sub>) and are presented as mean &#x000b1; SE of three experiments, each in duplicate. * Differences when treatments are compared to the basal activity <italic>p</italic> &#x0003c; 0.01 (Tukey&#x02019;s test).</p></caption><graphic xlink:href="pharmaceuticals-14-00111-g009"/></fig><fig id="pharmaceuticals-14-00111-f010" orientation="portrait" position="float"><label>Figure 10</label><caption><p>Effects of <italic>E. intisy</italic> EO (5&#x02013;50 &#x000b5;g/mL on 0.5 mM verapamil-stimulated P-gp ATPase activity. The data are expressed as luminescence (RLU) and are presented as mean &#x000b1; SE of three experiments, each in duplicate. Different letters represent significant differences (Tukey&#x02019;s test) in luminescence among the concentrations (<italic>p</italic> &#x0003c; 0.01).</p></caption><graphic xlink:href="pharmaceuticals-14-00111-g010"/></fig><table-wrap id="pharmaceuticals-14-00111-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-14-00111-t001_Table 1</object-id><label>Table 1</label><caption><p>Essential oil composition of <italic>E. intisy</italic>. Compounds belonging to the same chemical class and functional group are arranged according to Kovats Retention Indices (KRI) of the Supelcowax 10 capillary column.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">KRI</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Relative Amount %</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MS Similarity</th></tr></thead><tbody><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic>Aliphatic Acids</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2512</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dodecanoic acid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2720</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oleic acid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic>Aliphatic Alcohols</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1354</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1-Hexanol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1383</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(Z)-3-Hexen-1-ol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1407</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(E)-2-Hexen-1-ol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1557</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(E)-3-Octen-1-ol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1968</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1-Dodecanol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">85</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1557</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(E)-3-Octen-1-ol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2447</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1-Heptacosanol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.85</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic>Aliphatic Aldheydes</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1081</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hexanal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1217</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(E)-2-Hexenal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1389</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nonanal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic>Aliphatic Alkanes</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1900</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nonadecane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2200</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Docosane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2300</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tricosane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2400</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tetracosane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.44</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2500</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pentacosane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2600</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hexacosane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2700</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Heptacosane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.73</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic>Aliphatic Esters</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2550</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Methyl linolenate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic>Aromatic Esters</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2606</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Benzyl benzoate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic>Diterpene Alcohols</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2296</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Isophytol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2615</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phytol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.89</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic>Irregular Terpene Ketones</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2124</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hexahydrofarnesyl acetone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic>Miscellaneous Ketones</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1932</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(Z)-Jasmone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic>Monoterpene Alchols</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1550</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Linalool</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1612</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hotrienol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1849</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Geraniol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic>Monoterpene Ethers</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1435</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(Z)-Linalool oxide furanoid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic>Monoterpene Hydrocarbons</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1247</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(E)-beta-Ocimene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic>Monoterpene Ketones</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1629</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pulegone </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">82</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic>Sesquiterpene Alcohols</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1876</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">epi-Cubebol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">81</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2042</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nerolidol isomer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">75</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2073</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">beta-Elemol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2156</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">gamma-Eudesmol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2186</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pogostol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">83</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2206</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">alpha-Eudesmol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2213</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">beta-Eudesmol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.76</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">82</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2219</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">alpha-Cadinol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2231</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(&#x02013;)-Spathulenol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2262</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Valerenol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.46</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2281</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Juniper camphor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2354</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Farnesol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2492</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">gamma-Costol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic>Sesquiterpene Ethers</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1464</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(E)-Linalool oxide furanoid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1507</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vitispirane</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1510</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vitispirane isomer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Caryophyllene oxide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic>Sequiterpene Hydrocarbons</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1441</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">alpha-Cubebene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1470</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">alpha-Copaene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.94</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1495</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">beta-Bourbonene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1571</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">beta-Caryophyllene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1573</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(Z)-beta-Elemene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1622</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">gamma-Elemene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">82</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1644</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">alpha-Humulene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1666</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">alpha-Amorphene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.85</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1684</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">beta-Guaiene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1698</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">alpha-Selinene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1704</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">alpha-Muurolene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1736</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">delta-Cadinene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1742</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(E,E)-alpha-Farnesene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1759</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cubenene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1811</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Isocalamenene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1894</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">alpha-Calacorene </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1926</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neophytadiene </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1939</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">beta-Calacorene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">84</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1955</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neophytadiene isomer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1981</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neophytadiene isomer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1987</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">alpha-Gorgonene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic>Sesquiterpene Ketones</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2234</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mustakone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic>Unidentified</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2136</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown <italic>m/z</italic>: 161 (100), 105 (99), 43 (93), 121 (65), 93 (62), 81 (60), 95 (56), 119 (56), 79 (49), 91 (48)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2255</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown <italic>m/z</italic>: 107 (100), 93 (78), 105 (74), 119 (63), 69 (60), 41 (56), 81 (53), 91 (49), 79 (44), 161 (43)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NF</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2329</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown <italic>m/z</italic>: 105 (100), 143 (94), 91 (80), 107 (67), 81 (60), 119 (57), 79 (54), 93 (50), 147 (50), 121 (46)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.67</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">85</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Total</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>68.84</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table></table-wrap><table-wrap id="pharmaceuticals-14-00111-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-14-00111-t002_Table 2</object-id><label>Table 2</label><caption><p>IC<sub>50</sub> values of the three cell lines treated with the essential oil of <italic>E. intisy.</italic></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell Line </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> (Mean &#x000b1; SE)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HL-60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.0 &#x000b1; 0.7 &#x000b5;g/mL</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HL-60R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.5 &#x000b1; 0.07 &#x000b5;g/mL</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Caco-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62.5 &#x000b1; 0.35 &#x000b5;g/mL</td></tr></tbody></table></table-wrap><table-wrap id="pharmaceuticals-14-00111-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-14-00111-t003_Table 3</object-id><label>Table 3</label><caption><p>Effects of <italic>E. intisy</italic> EO on intracellular accumulation of doxorubicin in HL-60 and HL-60R cell lines. The cells were treated with EO 15 &#x003bc;g/mL or verapamil 10 &#x000b5;M. After 24 h of incubation, doxorubicin 1 &#x003bc;g/mL has been added for different time: 30 min, 1 h and 2 h. The intracellular accumulation of doxorubicin was measured by flow cytometric analysis. The results are presented as percentage of fluorescence intensity (means &#x000b1; standard error of three experiments).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Treatment</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Fluorescence %</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HL-60 </th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HL-60R</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">control</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2 &#x000b1; 0.004</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9 &#x000b1; 0.004</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">doxo 1 &#x000b5;g/mL 30 min</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0 &#x000b1; 0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6 &#x000b1; 0.09</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">doxo 1 &#x000b5;g/mL 1 h</td><td align="center" valign="middle" rowspan="1" colspan="1">9.7 &#x000b1; 0.70 *</td><td align="center" valign="middle" rowspan="1" colspan="1">8.8 &#x000b1; 0.09 *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">doxo 1 &#x000b5;g/mL 2 h</td><td align="center" valign="middle" rowspan="1" colspan="1">80.2 &#x000b1; 0.65 *</td><td align="center" valign="middle" rowspan="1" colspan="1">11.9 &#x000b1; 0.79 *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>E. intisy</italic> EO 15 &#x000b5;g/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">0.12 &#x000b1; 0.03</td><td align="center" valign="middle" rowspan="1" colspan="1">0.47 &#x000b1; 0.07</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">verapamil 10 &#x000b5;M</td><td align="center" valign="middle" rowspan="1" colspan="1">0.03 &#x000b1; 0.03</td><td align="center" valign="middle" rowspan="1" colspan="1">0.73 &#x000b1; 0.10 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>E. intisy</italic> EO + doxo 30 min</td><td align="center" valign="middle" rowspan="1" colspan="1">3.0 &#x000b1; 0.41 *</td><td align="center" valign="middle" rowspan="1" colspan="1">14.7 &#x000b1; 0.18 *<sup>,a</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>E. intisy</italic> EO + doxo 1 h</td><td align="center" valign="middle" rowspan="1" colspan="1">7.97 &#x000b1; 0.53 *</td><td align="center" valign="middle" rowspan="1" colspan="1">25.6 &#x000b1; 0.25 *<sup>,a</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>E. intisy</italic> EO + doxo 2 h</td><td align="center" valign="middle" rowspan="1" colspan="1">59.8 &#x000b1; 0.97 *</td><td align="center" valign="middle" rowspan="1" colspan="1">35.5 &#x000b1; 0.19 *<sup>,a</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">verapamil + doxo 30 min</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6 &#x000b1; 0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">31.1 &#x000b1; 0.05 *<sup>,a</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">verapamil + doxo 1 h</td><td align="center" valign="middle" rowspan="1" colspan="1">21.8 &#x000b1; 0.75 *<sup>,a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">53.5 &#x000b1; 0.24 *<sup>,a</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">verapamil + doxo 2 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91.7 &#x000b1; 0.70 *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">85.6 &#x000b1; 0.25 *<sup>,a</sup></td></tr></tbody></table><table-wrap-foot><fn><p>* <italic>p</italic> &#x0003c; 0.01, vs. the control. <sup>a</sup>
<italic>p</italic> &#x0003c; 0.01 represent significant differences among the treatments in combination with essential oil or verapamil compared to doxorubicin alone for the same time (one-way ANOVA followed by Tukey&#x02019;s test).</p></fn></table-wrap-foot></table-wrap><table-wrap id="pharmaceuticals-14-00111-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-14-00111-t004_Table 4</object-id><label>Table 4</label><caption><p>Cell growth assays of HL-60R cells following treatment with various concentrations of <italic>E.</italic> &#x000b1; standard error of three independent experiments.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell Growth Inhibition %</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>E. intisy</italic> EO 15 &#x000b5;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.0 &#x000b1; 1.4 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>E. intisy</italic> EO 20 &#x000b5;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.0 &#x000b1; 0.7 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>E. intisy</italic> EO 30 &#x000b5;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56.0 &#x000b1; 1.4 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">doxo 1 &#x000b5;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5 &#x000b1; 0.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">doxo 5 &#x000b5;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.7 &#x000b1; 3.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">doxo 10 &#x000b5;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.3 &#x000b1; 3.8 *</td></tr></tbody></table><table-wrap-foot><fn><p>* p &#x0003c; 0.01 vs. control (one-way ANOVA followed by Tukey&#x02019;s test). Data are expressed as the mean &#x000b1; standard error of three independent experiments.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pharmaceuticals-14-00111-t005" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-14-00111-t005_Table 5</object-id><label>Table 5</label><caption><p>Cell growth inhibition and combination indices in HL-60R cells following combination treatment with various concentrations of <italic>E. intisy</italic> EO and doxorubicin.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell Growth Inhibition %</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Combination Index</th></tr></thead><tbody><tr><td align="center" valign="middle" style="background:#F0F0F0" rowspan="1" colspan="1"><italic>E. intisy</italic> EO (15 &#x000b5;g/mL) + doxo (1 &#x000b5;g/mL) </td><td align="center" valign="middle" style="background:#F0F0F0" rowspan="1" colspan="1">17.0 &#x000b1; 0.5 *</td><td align="center" valign="middle" style="background:#F0F0F0" rowspan="1" colspan="1">0.80</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>E. intisy</italic> EO (15 &#x000b5;g/mL) + doxo (5 &#x000b5;g/mL) </td><td align="center" valign="middle" rowspan="1" colspan="1">40.0 &#x000b1; 4.0 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.82</td></tr><tr><td align="center" valign="middle" style="background:#F0F0F0" rowspan="1" colspan="1"><italic>E. intisy</italic> EO (15 &#x000b5;g/mL) + doxo (10 &#x000b5;g/mL) </td><td align="center" valign="middle" style="background:#F0F0F0" rowspan="1" colspan="1">58.0 &#x000b1; 3.4 *</td><td align="center" valign="middle" style="background:#F0F0F0" rowspan="1" colspan="1">0.83</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>E. intisy</italic> EO (20 &#x000b5;g/mL) + doxo (1 &#x000b5;g/mL) </td><td align="center" valign="middle" rowspan="1" colspan="1">24.0 &#x000b1; 0.7 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.85</td></tr><tr><td align="center" valign="middle" style="background:#F0F0F0" rowspan="1" colspan="1"><italic>E. intisy</italic> EO (20 &#x000b5;g/mL) + doxo (5 &#x000b5;g/mL) </td><td align="center" valign="middle" style="background:#F0F0F0" rowspan="1" colspan="1">59.3 &#x000b1; 1.8 *</td><td align="center" valign="middle" style="background:#F0F0F0" rowspan="1" colspan="1">0.88</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>E. intisy</italic> EO (20 &#x000b5;g/mL) + doxo (10 &#x000b5;g/mL) </td><td align="center" valign="middle" rowspan="1" colspan="1">64.3 &#x000b1; 3.2 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.88</td></tr><tr><td align="center" valign="middle" style="background:#F0F0F0" rowspan="1" colspan="1"><italic>E. intisy</italic> EO (30 &#x000b5;g/mL) + doxo (1&#x000b5;g/mL) </td><td align="center" valign="middle" style="background:#F0F0F0" rowspan="1" colspan="1">49.0 &#x000b1; 0.5 *</td><td align="center" valign="middle" style="background:#F0F0F0" rowspan="1" colspan="1">0.90</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>E. intisy</italic> EO (30 &#x000b5;g/mL) + doxo (5 &#x000b5;g/mL) </td><td align="center" valign="middle" rowspan="1" colspan="1">69.0 &#x000b1; 6.3 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.91</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;background:#F0F0F0" rowspan="1" colspan="1"><italic>E. intisy</italic> EO (30 &#x000b5;g/mL) + doxo (10 &#x000b5;g/mL) </td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F0F0F0" rowspan="1" colspan="1">81.6 &#x000b1; 0.9 *</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#F0F0F0" rowspan="1" colspan="1">0.88</td></tr></tbody></table><table-wrap-foot><fn><p>* <italic>p</italic> &#x0003c; 0.01 vs. control (one-way ANOVA followed by Tukey&#x02019;s test). Data are expressed as the mean &#x000b1; standard error of three independent experiments.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pharmaceuticals-14-00111-t006" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-14-00111-t006_Table 6</object-id><label>Table 6</label><caption><p>Cell death in HL-60R cells treated for 48 h with 25 &#x003bc;g/mL of <italic>E. intsy</italic> essential oil and different concentrations of doxorubicin, either alone or in combination.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">HL-60R</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Cell Death %</italic>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Expected %</italic>
</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.5 &#x000b1; 0.25</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">+ <italic>E.intisy</italic> EO 25 &#x000b5;g/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">5.1 &#x000b1; 0.10</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">+ doxo 2 &#x000b5;g/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">4.8 &#x000b1; 0.20</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">+ doxo 5 &#x000b5;g/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">8.6 &#x000b1; 0.10</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">+ doxo 10 &#x000b5;g/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">12.7 &#x000b1; 0.30</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">+ doxo 25 &#x000b5;g/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">15.0 &#x000b1; 0.15</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">+ <italic>E.intisy</italic> EO + doxo 2 &#x000b5;g/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">6.6 &#x000b1; 0.10</td><td align="center" valign="middle" rowspan="1" colspan="1">5.3 &#x000b1; 0.55</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">+ <italic>E.intisy</italic> EO + doxo 5 &#x000b5;g/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">17.6 &#x000b1; 0.35</td><td align="center" valign="middle" rowspan="1" colspan="1">9.1 &#x000b1; 0.45 *</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">+ <italic>E.intisy</italic> EO + doxo 10 &#x000b5;g/mL</td><td align="center" valign="middle" rowspan="1" colspan="1">21.6 &#x000b1; 0.20</td><td align="center" valign="middle" rowspan="1" colspan="1">13.2 &#x000b1; 0.65 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+ <italic>E.intisy</italic> EO + doxo 25 &#x000b5;g/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36.8 &#x000b1; 0.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.6 &#x000b1; 0.50 *</td></tr></tbody></table><table-wrap-foot><fn><p>* <italic>p</italic> &#x0003c; 0.01 vs. observed (one-way ANOVA followed by Tukey&#x02019;s test). Data are expressed as the mean &#x000b1; standard error of three independent experiments. Expected value: Sum of the effects of the agents alone minus that of the untreated cells.</p></fn></table-wrap-foot></table-wrap></floats-group></article>